Nicotinamide mononucleotide derivatives and their use in the treatment and prevention of anticancer drug-induced toxicity

Abstract

The present invention relates to nicotinamide mononucleotide derivatives of formula (I) for use in the treatment and / or prevention of antineoplastic drug-induced toxicity. The present invention further relates to pharmaceutical compositions comprising compounds of formula (I) for use in the treatment and / or prevention of antineoplastic drug-induced toxicity. [Formula 1] TIFF2023538259000153.tif35162

Description

[Technical Field]

[0001] Field of Invention The present invention relates to nicotinamide mononucleotide derivative compounds for use in the treatment and / or prevention of anticancer drug-induced toxicity. [Background technology]

[0002] Background of the Invention Drug-induced toxicity, such as cardiotoxicity, nephrotoxicity, neurotoxicity, hematological toxicity, or hepatotoxicity, is a significant cause of compound recall in preclinical and clinical development.

[0003] Notably, over the past 40 years, nearly 10% of drugs, such as rofecoxib, tegaserod, and sibutramine, have been recalled from clinical markets worldwide due to cardiovascular safety concerns. Despite considerable efforts to clarify cardiotoxicity in the preclinical phase of drug development, cardiotoxicity continues to pose safety concerns, primarily due to a lack of sufficient knowledge of the cardiotoxic mechanisms.

[0004] While all therapeutic drug classes possess unforeseen toxicity, toxicity can only become apparent after long-term accumulation of the drug or its metabolites. Therefore, toxicity induced by long-term administration of drugs such as neuropsychiatric / psychotropic agents and anticancer chemotherapy agents becomes a significant concern.

[0005] In particular, drug-induced cardiotoxicity, a form of myocardial dysfunction that can commonly progress to heart failure, represents the serious adverse effects of some common traditional anti-cancer drugs, such as anthracyclines, cyclophosphamide, fluorouracil (5-FU), and taxanes, as well as newer drugs such as biological monoclonal antibodies, such as trastuzumab, bevacizumab, and nivolumab; tyrosine kinase inhibitors, such as sunitinib and nilotinib; antiretroviral drugs, such as zidovudine; antidiabetic drugs, such as rosiglitazone; and some pleasure drugs such as alcohol, cocaine, methamphetamine, ecstasy, and synthetic cannabinoids.

[0006] Currently, it is estimated that more than one in three people will develop cancer in their lifetime, and along with cardiovascular disease, cancer is one of the two leading causes of death in developed countries. Thanks to improvements in cancer drug therapy, the current 10-year overall survival rate for cancer is as high as 50% for the 20 most common malignancies, and it is estimated that 33% of long-term cancer survivors die from heart disease.

[0007] Anthracycline-induced cardiotoxicity, and in particular cardiomyopathy induced by doxorubicin (DOX), are considered extremely serious adverse effects of tumor treatment.

[0008] Doxorubicin is one of the most widely used drugs for treating cancer in both adults and children. DOX-induced cardiotoxicity manifests in multiple forms, ranging from asymptomatic electrocardiogram (ECG) changes to decompensated cardiomyopathy characterized by reduced left ventricular ejection fraction. According to their clinical manifestations, these cardiotoxic events can be classified into three types: (1) acute, occurring during or immediately after treatment; (2) early-onset chronic progressive cardiotoxicity, occurring within one year of exposure to chemotherapy; and (3) late-onset chronic progressive cardiotoxicity, occurring more than one year after the completion of treatment.

[0009] Many studies have explored the pathophysiology and mechanisms of doxorubicin-induced cardiotoxicity, but the exact mechanism remains unclear and may be multifactorial.

[0010] Mitochondrial damage and apparent ROS production are thought to be the primary causes of cardiotoxicity. However, the use of ROS inhibitors to treat DOX cardiomyopathy has not been successful, and currently there are no established effective treatments available to treat DOX cardiomyopathy.

[0011] To date, standard management during anthracycline-based chemotherapy includes pre-treatment cardiac function assessment, monitoring of potential cardiotoxicity during treatment, and long-term follow-up after completion of chemotherapy.

[0012] Some protocols have been proposed to mitigate or treat doxorubicin / drug-induced cardiotoxicity, including the use of epirubicin as an alternative to doxorubicin; the combined use of antioxidants and iron chelators such as dexrazoxane, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, lanolazine, metformin, and hydroxymethylglutaryl coenzyme A reductase inhibitors; and the use of antioxidants such as quercetin, Q10 coenzyme, pyrroloquinoline quinone, vitamin E, and auto-nanoemulsified carnitine.

[0013] However, the effectiveness of these drugs varies depending on the patient and the clinical symptoms observed, and further trials are needed to evaluate whether the beneficial effects observed on cardiac function persist over several years.

[0014] Therefore, there is an urgent need for effective and safe prophylactic and / or therapeutic measures for drug-induced toxicity, particularly that induced by anti-cancer drugs. [Overview of the project] [Problems that the invention aims to solve]

[0015] Therefore, an object of the present invention is to provide safe prophylactic and / or therapeutic treatment for antineoplastic drug-induced toxicity by providing nicotinamide mononucleotide of formula 001 and its derivatives for use in the treatment and / or prevention of antineoplastic drug-induced toxicity, particularly antineoplastic drug-induced cardiotoxicity.

[0016] Surprisingly, the applicant has found that the nicotinamide mononucleotide derivative according to the present invention is a potent agent for treating and / or preventing anti-cancer drug-induced cardiotoxicity, particularly doxorubicin-induced cardiotoxicity, and is well-tolerated. [Means for solving the problem]

[0017] overview Therefore, the present invention relates to a compound of formula (I) for use in the treatment of anti-cancer drug-induced toxicity, [Chemical Formula] wherein, X is selected from O, CH2, S, Se, CHF, CF2 and C=CH2; R1 is selected from H, azide, cyano, (C1-C8) alkyl, (C1-C8) thio-alkyl, (C1-C8) heteroalkyl and OR, where R is selected from H and (C1-C8) alkyl; R2, R3, R4 and R5 are independently selected from H, halogen, azide, cyano, hydroxyl, (C1-C 12 ) alkyl, (C1-C 12 ) thio-alkyl, (C1-C 12 ) heteroalkyl, (C1-C 12 ) haloalkyl and OR; where R is selected from H, (C1-C 12 ) alkyl, -C(O)(C1-C 12 ) alkyl, -C(O)NH(C1-C 12 ) alkyl, -C(O)O(C1-C 12 ) alkyl, -C(O)aryl, -C(O)(C1-C 12 ) alkyl-(C5-C 12 ) aryl, -C(O)NH(C1-C 12 ) alkyl-(C5-C 12 ) aryl, -C(O)O(C1-C 12 ) alkyl-(C5-C 12 ) aryl and -C(O)CHR AA NH2, where R AA is a side chain selected from proteinogenic amino acids; R6 is selected from H, azide, cyano, (C1-C8) alkyl, (C1-C8) thio-alkyl, (C1-C8) heteroalkyl and OR, where R is selected from H and (C1-C8) alkyl; R7 is selected from H, P(O)R9R 10 , P(S)R9R 10 and [ka] Selected from; here, R9 and R 10 These are independently OH, OR 11 , NR 13 R 14 , (C1~C8) alkyl, (C2~C8) alkenyl, (C2~C8) alkynyl, (C3~C 10 )Cycloalkyl, (C5~C 12 )Aaryl, (C5~C 12 )aryl-(C1~C8)alkyl, (C1~C8)alkyl-(C5~C 12 )aryl, (C1-C8) heteroalkyl, (C3-C8) heterocycloalkyl, (C5-C 12 ) Heteroaryl and NHCR α R α’ C(O)OR 12 Selected from; here - R 11 (C1~C 10 ) alkyl, (C3~C 10 )Cycloalkyl, (C5~C 12 )aryl, (C1~C 10 )alkyl-(C5~C 12 ) Aryl, substitution (C5~C 12 )aryl, (C1~C 10 ) Heteroalkyl, (C1~C 10 ) Haloalkyl, -(CH2) m C(O)(C1~C 15 ) Alkyl, -(CH2) m OC(O)(C1~C 15 ) Alkyl, -(CH2) m OC(O)O(C1~C 15 ) Alkyl, -(CH2) m SC(O)(C1~C 15 ) Alkyl, -(CH2) m C(O)O(C1~C 15 ) Alkyl, -(CH2) m C(O)O(C1~C 15 )alkyl-(C5~C 12)aryl (where m is an integer selected from 1 to 8) and -P(O)(OH)OP(O)(OH)2, as well as selected from internal or external counterions; - R 12 is hydrogen, (C1~C 10 )alkyl, (C2~C8)alkenyl, (C2~C8)alkynyl, (C1~C 10 ) Haloalkyl, (C3~C 10 )Cycloalkyl, (C3~C 10 ) Heterocycloalkyl, (C5~C 12 )aryl, (C1~C4)alkyl-(C5~C 12 )aryl and (C5~C 12 ) selected from heteroaryl groups; where the aryl or heteroaryl group is optionally substituted with one or two groups selected from halogens, trifluoromethyl, (C1-C6) alkyl, (C1-C6) alkoxy, and cyano groups; - R 13 and R 14 These are independently H, (C1~C8)alkyl and (C1~C8)alkyl-(C5~C 12 ) Selected from the arrow; - R α and R α’ Independently, hydrogen, (C1~C 10 ) Alkyl, (C2~C 10 ) Alkenil, (C2~C 10 ) Alkinyl, (C3~C 10 )Cycloalkyl, (C1~C 10 ) Thio-alkyl, (C1~C 10 ) Hydroxyalkyl, (C1~C 10 )alkyl-(C5~C 12 )Aaryl, (C5~C 12 )aryl, -(CH2)3NHC(=NH)NH2, (1H-indole-3-yl)methyl, (1H-imidazole-4-yl)methyl and side chains selected from protein-constitutive or non-protein-constitutive amino acids; where the aryl group is hydroxyl, (C1~C 10) optionally substituted by a group selected from alkyl, (C1-C6) alkoxy, halogen, nitro and cyano; or R9 and R 10 together with the phosphorus atom to which they are attached form a 6-membered ring, where -R9-R 10 - represents -O-CH2-CH2-CHR-O-, where R is selected from hydrogen, (C5-C6) aryl and (C5-C6) heteroaryl; said aryl or heteroaryl group is optionally substituted by one or two groups selected from halogen, trifluoromethyl, (C1-C6) alkyl, (C1-C6) alkoxy and cyano; X’ is selected from O, CH2, S, Se, CHF, CF2 and C=CH2; R 1’ is selected from H, azide, cyano, (C1-C8) alkyl, (C1-C8) thio-alkyl, (C1-C8) heteroalkyl and OR; where R is selected from H and (C1-C8) alkyl; R 2’ , R 3’ , R 4’ and R 5’ are independently selected from H, halogen, azide, cyano, hydroxyl, (C1-C 12 ) alkyl, (C1-C 12 ) thio-alkyl, (C1-C 12 ) heteroalkyl, (C1-C 12 ) haloalkyl and OR; where R is selected from H, (C1-C 12 ) alkyl, -C(O)(C1-C 12 ) alkyl, -C(O)NH(C1-C 12 ) alkyl, -C(O)O(C1-C 12 ) alkyl, -C(O) aryl, -C(O)(C1-C 12 ) alkyl-(C5-C 12 ) aryl, -C(O)NH(C1-C 12 ) alkyl-(C5-C 12 ) aryl, -C(O)O(C)-C 12 ) alkyl-(C5-C 12 ) aryl and -C(O)CHRAA selected from NH2; where R AA is a side chain selected from the protein - forming amino acids; R 6’ is selected from H, azide, cyano, (C1 - C8) alkyl, (C1 - C8) thio - alkyl, (C1 - C8) heteroalkyl and OR; where R is selected from H and (C1 - C8) alkyl; R 8’ is selected from H, OR, NR 15’ R 16’ NH - NHR 15’ SH, CN, N3 and halogen; where R is selected from H and (C1 - C8) alkyl, R 15’ and R 16’ are independently selected from H, (C1 - C8) alkyl and (C1 - C8) alkyl - (C5 - C 12 ) aryl and - CHR AA’ CO2H; where R AA’ is a side chain selected from protein - forming or non - protein - forming amino acids; Y’ is selected from CH, CH2, CHCH3, C(CH3)2 and CCH3; n is an integer selected from 1 - 3;

Chemical formula

Chemical formula

Chemical formula

[0018] According to one embodiment, X represents oxygen.

[0019] According to one embodiment, R1 and R6 are identical and represent hydrogen.

[0020] According to one embodiment, R3 and R4 are the same and represent hydrogen.

[0021] According to one embodiment, R2 and R5 are the same and represent OH.

[0022] According to one embodiment, Y is selected from CH and CH2.

[0023] According to one embodiment, R7 is H, P(O)R9R10 and [ka] (Here, R9 and R 10 This is as stated above in this specification; X' is oxygen; R 1’ and R 6’ Each of these represents hydrogen; R 2’ , R 3’ , R 4’ , and R 5’ These are independently selected from hydrogen and OH; R 8’ It is NH2; Y' is selected from CH and CH2; n is 2; [ka] represents a junction; [ka] Y' represents a single or double bond; [ka] R 1’ (Represents either alpha or beta anomer depending on its position) Selected from.

[0024] According to one embodiment, R8 is NH2.

[0025] According to one embodiment, the compounds for use according to the present invention are selected from compounds 001 to 014, as well as their pharmaceutically acceptable salts and solvates: [Table 1] TIFF0007842734000013.tif161162

[0026] According to one embodiment, toxicity is induced by an anti-cancer agent selected from anthracyclines, alkylating agents, taxanes, antimetabolites, bioresponse modifiers, histone deacetylase inhibitors, hormones, vinca alkaloids, topoisomerase inhibitors, monoclonal antibodies, tyrosine kinase inhibitors, and mixtures thereof.

[0027] According to one embodiment, toxicity is induced by an anthracycline selected from doxorubicin, daunorubicin, epirubicin, idarubicin, bleomycin, mitomycin, mitoxantrone, plicamycin, and barurubicin.

[0028] According to one embodiment, toxicity is induced by doxorubicin.

[0029] According to one embodiment, toxicity is cardiotoxicity selected from heart failure, left ventricular failure, myocardial ischemia, myocardial infarction, QT prolongation, torsades de pointe, arrhythmia, pericarditis, myocarditis, bradycardia, hypertension, and thromboembolism.

[0030] The present invention also relates to a pharmaceutical composition for use in the treatment of toxicity, comprising at least one compound for use according to the present invention and at least one pharmaceutically acceptable carrier.

[0031] According to one embodiment, the pharmaceutical composition for use, in addition to at least one compound for use as described herein, includes natural extracts; anti-cancer agents; antidepressants; antiretroviral agents; beta-blockers; antidiabetic agents; diuretics; antihypertensive agents; antiarrhythmic agents; CNS stimulants; antimalarial agents; immunosuppressants; antifungal agents; cytokines; interferons; anabolic steroids; adrenergic stimulants; neuromodulators; COX inhibitors; angiotensin-converting enzyme inhibitors; angiotensin receptor blockers; lanolazine; metformin; and electrocorticoid receptor blockers. It contains at least one active ingredient selected from: pharmacokinetic antagonists; hydroxymethylglutaryl coenzyme A reductase inhibitors; antioxidants such as quercetin self-nanoemulsifying formulations; Q10 coenzyme; vitamin E; L-carnitine; steroids; cyclosporine; mycophenolate mofetil; anti-TNF drugs such as influximab or etanercept; anti-IL1 such as Sraninka; anti-PGF such as Gleevec; anti-CD20 such as rituximab; maltol; PTEN modifiers; nobiletin; pyrroloquinoline quinone; and urolithin.

[0032] definition The following definitions and explanations relate to terms used throughout the application, including both the specification and the claims.

[0033] When describing the compounds of the present invention, terms used should be interpreted according to the following definitions unless otherwise specified.

[0034] Unless otherwise specified, substituents not explicitly defined herein are named by listing the names of the adjacent functional groups toward the bonding site, followed by the names of the terminal portions of the functional groups. For example, the substituent "arylalkyl" refers to the group -(aryl)-(alkyl).

[0035] In this invention, the following terms have the following meanings:

[0036] The term "alkyl," either alone or as part of another substituent, is derived from the formula C n H2n+1This refers to a hydrocarbyl radical represented by the formula (wherein n is a number of 1 or more). Generally, the alkyl group of the present invention contains 1 to 12 carbon atoms, preferably 1 to 10 carbon atoms, preferably 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms, and even more preferably 1 to 2 carbon atoms. The alkyl group may be linear or branched. Suitable alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, and t-butyl, pentyl and its isomers (e.g., n-pentyl, iso-pentyl), hexyl and its isomers (e.g., n-hexyl, isohexyl), heptyl and its isomers (e.g., n-heptyl, iso-heptyl), octyl and its isomers (e.g., n-octyl, iso-octyl), nonyl and its isomers (e.g., n-nonyl, iso-nonyl), decyl and its isomers (e.g., n-decyl, iso-decyl), undecyl and its isomers, and dodecyl and its isomers. Preferred alkyl groups include methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, s-butyl, t-butyl, n-pentyl, n-hexyl, n-heptyl, n-octyl, n-nonyl, and n-decyl.Examples of saturated branched alkyl groups include i-propyl, s-butyl, i-butyl, t-butyl, i-pentyl, 2-methylbutyl, 3-methylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2,3-dimethylbutyl, 2,3-dimethylpentyl, 2,4-dimethylpentyl, 2,3-dimethylhexyl, 2,4-dimethylhexyl, 2,5-dimethylhexyl, 2,2-dimethylpentyl, 2,2-dimethylhexyl, and 3,3-dimethylpentyl. Examples include, but are not limited to, pentyl, 3,3-dimethylhexyl, 4,4-dimethylhexyl, 2-ethylpentyl, 3-ethylpentyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, 2-methyl-4-ethylpentyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2-methyl-4-ethylhexyl, 2,2-diethylpentyl, 3,3-diethylhexyl, 2,2-diethylhexyl, and 3,3-diethylhexyl.

[0037] Cx-Cy-alkyl refers to an alkyl group containing x to y carbon atoms.

[0038] When the suffix "-ene" ("alkylene") is used in conjunction with alkyl groups, it means an alkyl group as defined herein having two single bonds as bonding sites to other groups. The term "alkylene" includes methylene, ethylene, methylmethylene, propylene, ethylethylene, and 1,2-dimethylethylene.

[0039] As used herein, the term "alkenyl" refers to an unsaturated hydrocarbyl group that contains one or more carbon-carbon double bonds and may be linear or branched. Suitable alkenyl groups contain between 2 and 12 carbon atoms, preferably between 2 and 8 carbon atoms, and more preferably between 2 and 6 carbon atoms. Examples of alkenyl groups include ethenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl and its isomers, 2-hexenyl and its isomers, 2,4-pentadienyl and its isomers, and the like.

[0040] As used herein, the term "alkynyl" refers to a class of monounsaturated hydrocarbyl groups, where unsaturation arises from the presence of one or more carbon-carbon triple bonds. Alkynyl groups typically, and preferably, have the same number of carbon atoms as alkenyl groups. Non-limiting examples of alkynyl groups include ethynyl, 2-propynyl, 2-butynyl, 3-butynyl, 2-pentynyl and its isomers, 2-hexynyl and its isomers, and the like.

[0041] As used herein, the term "alkoxy" refers to any -O-alkyl group, where alkyl is as defined above. Suitable alkoxy groups include, for example, methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, t-butoxy, sec-butoxy, and n-pentoxy.

[0042] As used herein, the term "amino acid" refers to alpha-aminated carboxylic acids, that is, molecules comprising a carboxylic acid functional group and an amine functional group at the alpha position of the carboxylic acid group, such as protein-constituting amino acids or non-protein-constituting amino acids.

[0043] As used herein, the term “aryl” refers to a polyunsaturated aromatic hydrocarbyl group having monocyclic (i.e., phenyl) or polycyclic aromatic rings fused to each other (e.g., naphthyl) or covalently linked, typically containing 5 to 12, preferably 6 to 10, atoms, with at least one ring being aromatic. The aromatic rings may optionally contain one or two additional rings (either cycloalkyl, heterocyclyl, or heteroaryl). The term “aryl” is also intended to encompass the partially hydrogenated carbocyclic derivatives listed herein. Non-limiting examples of aryls include phenyl, biphenyl, biphenylenyl, 5- or 6-tetralinyl, naphthalene-1- or -2-yl, 4-, 5-, 6- or 7-indenyl, 1-, 2-, 3-, 4- or 5-acenaphthenyl, 3-, 4- or 5-acenaphthenyl, 1- or 2-pentalenyl, 4- or 5-indanyl, 5-, 6-, 7- or 8-tetrahydronaphthyl, 1,2,3,4-tetrahydronaphthyl, 1,4-dihydronaphthyl, and 1-, 2-, 3-, 4- or 5-pyrenyl.

[0044] As used herein, the term "cycloalkyl" refers to a cyclic alkyl, alkenyl, or alkynyl group, i.e., a monovalent saturated or unsaturated hydrocarbyl group having one or two cyclic structures. Cycloalkyls include monocyclic or bicyclic hydrocarbyl groups. A cycloalkyl group may contain three or more carbon atoms in its ring, and generally, according to the present invention, it may contain 3 to 10 carbon atoms, more preferably 3 to 8 carbon atoms, and even more preferably 3 to 6 carbon atoms. Examples of cyclohexyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl, with cyclopropyl being particularly preferred.

[0045] The term "halo" or "halogen" refers to fluoro, chloro, bromo, or iodine groups. Preferred halo groups are fluoro and chloro.

[0046] The term "haloalkyl," either alone or as part of another group, refers to an alkyl radical having the meaning defined above, in which one or more hydrogen atoms are replaced by the halogens defined above. Non-limiting examples of such haloalkyl radicals include chloromethyl, 1-bromoethyl, fluoromethyl, difluoromethyl, trifluoromethyl, 1,1,1-trifluoroethyl, and so on. x ~C y - A haloalkyl group is a haloalkyl group containing x to y carbon atoms. Preferred haloalkyl groups are difluoromethyl and trifluoromethyl.

[0047] The term "heteroalkyl" means an alkyl group as defined above, in which one or more carbon atoms are replaced by heteroatoms selected from oxygen, nitrogen, and sulfur atoms. In a heteroalkyl group, the heteroatoms are linked only to carbon atoms along the alkyl chain, i.e., each heteroatom is separated from any other heteroatoms by at least one carbon atom. However, the nitrogen and sulfur heteroatoms may be oxidized, and the nitrogen heteroatom may be quaternized. The heteroalkyl group is bonded to another group or molecule only through carbon atoms, i.e., the bonded atom is not selected from the heteroatoms contained in the heteroalkyl group.

[0048] When at least one carbon atom in the aryl group is replaced by a heteroatom, the resulting ring is referred to herein as a heteroaryl ring.

[0049] As used herein, the term "heteroaryl," either alone or as part of another group, means, non-limitingly, a ring system containing one or two aromatic rings of 5 to 12 carbon atoms or typically 5 to 6 atoms each, fused to one another or covalently linked; at least one of which is aromatic, and one or more carbon atoms in one or more of these rings are replaced by oxygen, nitrogen, and / or sulfur atoms, the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. Such rings may be fused to aryl, cycloalkyl, heteroaryl, or heterocyclyl rings.Non-limiting examples of such heteroaryls include furanyl, thiophenyl, pyrazolyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, triazolyl, oxadiazolyl, thiadiazolyl, tetrazolyl, oxatriazolyl, thiatriazolyl, pyridinyl, pyrimidinyl, pyrazinyl, pyridadinyl, oxazinyl, dioxynyl, thiadinyl, triazinyl, imidazo[2,1-b][1,3]thiazolyl, thieno[3,2-b]furanyl, thieno[3,2-b]thiophenyl, thieno[2,3-d][l,3]thiazolyl, thieno[2,3-d]imidazolyl, tetrazolo[l,5-a]pyridinyl, indolyl, indolidinyl, isoindolyl, benzofuranyl, isobenzofuranyl, benzothiophenyl, isobenzothiophenyl Indazolyl, benzimidazolyl, 1,3-benzoxazolyl, 1,2-benzoisoxazolyl, 2,1-benzoisoxazolyl, 1,3-benzothiazolyl, 1,2-benzoisothiazolyl, 2,1-benzoisothiazolyl, benzotriazolyl, 1,2,3-benzoxadiazolyl, 2,1,3-benzoxadiazolyl, 1,2,3-benzothiadiazolyl, 2,1,3-be Examples include nzothiasiazolyl, thienopyridinyl, purinyl, imidazo[l,2-a]pyridinyl, 6-oxopyridazine-l(6H)-yl, 2-oxopyridine-l(2H)-yl, 6-oxopyridazine-l(6H)-yl, 2-oxopyridine-l(2H)-yl, 1,3-benzodioxolyl, quinolinyl, isoquinolinyl, sinnolinyl, quinazolinyl, and quinoxalinyl.

[0050] When at least one carbon atom in a cycloalkyl group is replaced by a heteroatom, the resulting ring is referred to herein as a "heterocycloalkyl" or "heterocyclyl".

[0051] As used herein, the terms “heterocyclyl,” “heterocycloalkyl,” or “heterocyclo,” either alone or as part of another group, refer to a non-aromatic, fully saturated or partially saturated cyclic group having at least one heteroatom in at least one carbon-carbon-containing ring (e.g., a 3- to 7-membered monocyclic, a 7- to 11-membered bicyclic, or containing a total of 3 to 10 ring atoms). Each ring of a heterocyclic group containing heteroatoms may have 1, 2, 3, or 4 heteroatoms selected from nitrogen, oxygen, and / or sulfur atoms, the nitrogen and sulfur heteroatoms may optionally be oxidized, and the nitrogen heteroatom may optionally be quaternized. Any of the carbon atoms of the heterocyclic group may be substituted with an oxo (e.g., piperidone, pyrrolidinone). The heterocyclic group may be bonded to any heteroatom or carbon atom of the ring or ring system, as long as the valence is acceptable. The rings of a polycyclic heterocycle may be condensed, bridged, and / or joined through one or more spiroatoms. Examples of heterocyclic groups that are not limited to these include oxetanyl, piperidinyl, azetidinyl, 2-imidazolinyl, pyrazolinyl, imidazolidinyl, isoxazolinyl, oxazolidinyl, isoxazolidinyl, thiazolidinyl, isothiazolidinyl, piperidinyl, 3H-indolyl, indolinyl, isoindolinyl, 2-oxopiperazinyl, piperazinyl, homopiperazinyl, 2-pyrazolidinyl, 3-pyrazolidinyl, tetrahydro-2H-pyranyl, 2H-pyranyl, 4H-pyranyl, 3,4-dihydro-2H-pyranyl, 3-dioxolanyl, 1,4-dioxolanyl, 2,5-dioxoimidal Examples include zolidinyl, 2-oxopiperidinyl, 2-oxopyrrodinyl, tetrahydropyranil, tetrahydrofuranil, tetrahydroquinolinyl, tetrahydroisoquinoline-1-yl, tetrahydroisoquinoline-2-yl, tetrahydroisoquinoline-3-yl, tetrahydroisoquinoline-4-yl, thiomorpholine-4-yl, thiomorpholine-4-yl sulfoxide, thiomorpholine-4-yl sulfone, 1,3-dioxolanil, 1,4-oxathianil, 1H-pyrrolidinyl, tetrahydro-1,1-dioxothiophenyl, N-formylpiperazinyl, and morpholine-4-yl.

[0052] The term "hydroxyalkyl" refers to an alkyl radical having the meaning defined above, in which one or more hydrogen atoms are replaced by an -OH moiety.

[0053] The term "thio-alkyl" refers to an alkyl radical having the meaning defined above, in which one or more hydrogen atoms are replaced by an -SH moiety.

[0054] As used herein, the term “non-proteinogenic amino acid” refers to an amino acid that is not naturally encoded or found in the genetic code of any living organism. Non-limiting examples of non-proteinogenic amino acids include ornithine, citrulline, argininosuccinate, homoserine, homocysteine, cysteinesulfinic acid, 2-aminomuconic acid, δ-aminolevulinic acid, β-alanine, cystathionine, γ-aminobutyrate, DOPA, 5-hydroxytryptophan, D-serine, ibotenic acid, α-aminobutyrate, 2-aminoisobutyrate, D-leucine, D-valine, D-alanine, or D-glutamate.

[0055] As used herein, the term "protein-constituting amino acid" refers to the amino acids incorporated into proteins during the translation of messenger RNA by ribosomes in living organisms, namely alanine (ALA), arginine (ARG), asparagine (ASN), aspartate (ASP), cysteine ​​(CYS), glutamate (gLU), glutamine (GLN), glycine (GLY), histidine (HIS), isoleucine (ILE), leucine (LEU), lysine (LYS), methionine (MET), phenylalanine (PHE), proline (PRO), pyrrolicine (PYL), selenocysteine ​​(SEL), serine (SER), threonine (THR), tryptophan (TRP), tyrosine (TYR), or valine (VAL).

[0056] As used herein, the term “prodrug” means a pharmacodynamically acceptable derivative of a compound of formula (I), such as an ester, whose in vivo bioconversion product is an active drug. Prodrugs are characterized by increased bioavailability and are readily metabolized in vivo to the active compound. Suitable prodrugs for the purposes of the present invention include phosphoramidates, HepDirect, (S)-acyl-2-thioenyl (SATE), carboxylic acid esters, particularly alkyl esters, aryl esters, acyloxyalkyl esters, and dioxolene carboxylic acid esters; ascorbic acid esters.

[0057] The terms “substituent” or “substituted” mean that a hydrogen radical of a compound or group is replaced by any desired group, when the compound or group is substantially stable under reaction conditions in its unprotected form or is protected by a protecting group. Examples of preferred substituents include halogens (chloro, iodo, bromo, or fluoro); alkyl; alkenyl; alkynyl as described above; hydroxy; alkoxy; nitro; thiol; thioether; imine; cyano; amide; phosphonato; phosphine; carboxyl; thiocarbonyl; sulfonyl; sulfonamide; ketone; aldehyde; ester; oxygen (-O); haloalkyl (e.g., trifluoromethyl); cycloalkyl (e.g., cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl), which may be monocyclic, condensed polycyclic, or uncondensed polycyclic; or heterocycloalkyl (e.g., pyrrolidinyl, pipe), which may be monocyclic, condensed polycyclic, or uncondensed polycyclic. Examples include, but are not limited to, lysinyl, piperazinyl, morpholinyl, or thiadinyl, monocyclic, fused polycyclic, or unfused polycyclic aryl or heteroaryl groups (e.g., phenyl, naphthyl, pyrrolyl, indolyl, furanyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, pyrazolyl, pyridinyl, quinolinyl, isoquinolinyl, acridinyl, pyrazinyl, pyridadinyl, pyrimidinyl, benzimidazolyl, benzothiophenyl, or benzofuranyl); aminos (primary, secondary, or tertiary); CO2CH3; CONH2; OCH2CONH2; NH2; SO2NH2; OCHF2; CF3; OCF3; and such groups may also be optionally substituted by fused ring structures or bridges, e.g., -OCH2O-. These substituents may be optionally further substituted with substituents selected from such groups. In certain embodiments, the term "substituent" or the adjective "substituted" means alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, heterocycloalkyl, aryl, heteroaryl, arylalkyl, heteroarylalkyl, haloalkyl, -C(O)NR 17 R 18 , -NR19 C(O)R 20 Hello, -OR 19 ,cyano, nitro, haloalkoxy, -C(O)R 19 , -NR 17 R 18 , -SR 19 , -C(O)OR 19 -OC(O)R 19 , -NR 19 C(O)NR 17 R 18 -OC(O)NR 17 R 18 , -NR 19 C(O)OR 20 , -S(O) r R 19 , -NR 19 S(O) r R 20 , -OS(O) r R 20 , S(O) r NR 17 R 18 -O, -S, and -NR 19 R refers to a substituent selected from the group consisting of , where r is 1 or 2; 17 and R 18 Independently with respect to each presence, is H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, or optionally substituted heteroarylalkyl; or R 17 and R 18 R is a heterocycloalkyl or heteroaryl molecule that is optionally substituted along with the nitrogen to which it is bound; 19 and R 20Independently with respect to each presence, these are H, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkenyl, optionally substituted heterocycloalkyl, optionally substituted aryl, optionally substituted heteroaryl, optionally substituted arylalkyl, or optionally substituted heteroarylalkyl. In certain embodiments, the term “substituted” or the adjective “substituted” refers to the solubilizing group.

[0058] The bond of the chiral carbon is represented by the solid triangle in this specification. [ka] dashed triangle [ka] or wavy line [ka] It can be expressed using

[0059] The term "active ingredient" refers to a molecule or substance that, when administered to a target, slows or halts the progression, worsening, or aggravation of one or more symptoms of a disease or condition; a molecule or substance that alleviates the symptoms of a disease or condition; or a molecule or substance that cures a disease or condition. According to one embodiment, the therapeutic ingredient is a small molecule, either natural or synthetic. According to another embodiment, the therapeutic ingredient is a biomolecule such as oligonucleotides, siRNAs, miRNAs, DNA fragments, aptamers, or antibodies.

[0060] The term “administer” or its variations (e.g., “to administer”) means to provide an activator or active ingredient, either alone or as part of a pharmaceutically acceptable composition, to the subject whose condition, symptoms, or disease is to be treated.

[0061] The term “drug” refers to any substance that, when administered to a subject, causes an alteration in the subject’s physiological or psychological state. In the context of this invention, “drug” encompasses both drugs for medical use (“pharmaceuticals” or “active ingredients”) and drugs for non-medical use, such as pleasure drugs (e.g., psychotropic drugs).

[0062] "Pharmacologically acceptable" means that the components of a pharmaceutical composition are compatible with each other and are not harmful to the patient.

[0063] The terms “pharmaceutically acceptable excipient,” “pharmaceutically acceptable carrier,” or “pharmaceutical vehicle” refer to an inert medium or carrier used as a solvent or diluent in which the pharmaceutically active ingredient is formulated and / or administered and does not produce adverse reactions, allergic reactions, or other reactions when administered to animals, preferably humans. This includes all solvents, dispersions, coatings, antimicrobial and antifungal agents, isotonic agents, absorption retarders, and other similar components. For human administration, the preparation must meet the sterility, overall safety, and purity standards required by regulatory authorities such as the FDA or EMA. For the purposes of this invention, “pharmaceutically acceptable excipient” includes all pharmaceutically acceptable excipients, as well as all pharmaceutically acceptable carriers, diluents, and / or adjuvants.

[0064] The term "pharmaceutically acceptable salt" includes both acid addition salts and basic salts. Suitable acid addition salts are formed from acids that form non-toxic salts. Examples include acetate, adipine, aspartate, benzoate, besilate, bicarbonate / carbonate, bisulfate / sulfate, borate, cansilate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, mesilate, methylsulfate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogen phosphate / dihydrogen phosphate, pyroglutamic acid, sugarate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate, and xinafoate.

[0065] Suitable basic salts are formed from bases that form non-toxic salts. Examples include aluminum salts, arginine salts, benzathine salts, calcium salts, choline salts, diethylamine salts, 2-(diethylamino)ethanol salts, diolamine salts, ethanolamine salts, glycine salts, 4-(2-hydroxyethyl)-morpholine salts, lysine salts, magnesium salts, meglumine salts, morpholine salts, olamine salts, potassium salts, sodium salts, tromethamine salts, and zinc salts.

[0066] Hemi salts of acids and bases, such as hemisulfates and hemicalcium salts, may also be formed.

[0067] A pharmaceutically acceptable salt of the compound of formula (I) may be prepared by one or more of these methods: (i) by reacting the compound of formula (I) with the desired acid; (ii) By reacting the compound of formula (I) with the desired base; (iii) by removing an acid or salt-unstable protecting group from a suitable precursor of the compound of formula (I), or by ring-opening a suitable cyclic precursor, such as a lactone or lactam, using a desired acid; and / or (iv) By converting one salt of the compound of formula (I) to another salt by reaction with a suitable acid or by using a suitable ion exchange column.

[0068] All of these reactions typically take place in solution. The salt may precipitate from the solution and be collected by filtration, or recovered by evaporation of the solvent. The degree of ionization in the salt can vary from completely ionized to nearly non-ionized.

[0069] Generally, with respect to salts of the compounds of the present invention, pharmaceutically acceptable salts are preferred, but it should be noted that the present invention, in its broadest sense, also includes pharmaceutically unacceptable salts that can be used, for example, for the isolation and / or purification of the compounds of the present invention. For example, a diastereoisomer salt that can facilitate the separation of optically active isomers of the compound of formula (I) may be formed using a salt formed with an optically active acid or base.

[0070] The term "solvate" is used herein to describe a molecular complex comprising the compound of the present invention and containing one or more pharmaceutically acceptable solvent molecules, such as ethanol, in stoichiometric or lesser amounts. The term "hydrate" refers to a solvate when the solvent is water.

[0071] The term "human" refers to subjects of both sexes and any developmental stage (i.e., newborn, infant, adolescent, young adult, or adult).

[0072] The term "subject" refers to a mammal, preferably a human. According to the present invention, the subject is a mammal, preferably a human, that is suffering from and / or is susceptible to developing antineoplastic drug-induced toxicity. In one embodiment, the subject is a "patient," i.e., a mammal, preferably a human, who is waiting to receive medical treatment, receiving medical treatment, or has been / is / will be subject to a medical procedure, or is being monitored for the development of antineoplastic drug-induced toxicity.

[0073] As used herein, the term “therapeutic effective dose” (or more simply, “effective dose”) refers to the amount of an activator or active ingredient intended to prevent, reduce, alleviate or slow one or more symptoms of antineoplastic drug-induced toxicity without causing significant negative or adverse side effects in a subject requiring treatment.

[0074] As used herein, the terms “to treat,” “to treat,” or “treatment” refer to a therapeutic treatment, a prophylactic (or preventive) treatment, or both a therapeutic and a prophylactic (or preventive) treatment, whose purpose is to prevent, reduce, mitigate, and / or slow down (reduce) one or more symptoms of drug-induced toxicity, particularly anti-cancer drug-induced toxicity, in a subject of interest. In one embodiment, “to treat” or “treatment” refers to a therapeutic treatment. In another embodiment, “to treat” or “treatment” refers to a prophylactic or preventive treatment. In yet another embodiment, “to treat” or “treatment” refers to both a prophylactic (or preventive) treatment and a therapeutic treatment.

[0075] The term "toxicity" refers to a condition that causes damage to an organism, such as cardiotoxicity, nephrotoxicity, neurotoxicity, hematological toxicity, hepatotoxicity, lymphotoxicity, gastrointestinal toxicity, cutaneous toxicity, metabolic toxicity, ototoxicity, reproductive toxicity, osteotoxicity, genotoxicity, and bladder toxicity. According to the present invention, toxicity can be caused by the direct or indirect effects of molecules or substances on organs, tissues, or systems, such as drugs, alcohols, or heavy metals. Toxicity can also be caused by, for example, at least one disease or disorder.

[0076] The term "cardiotoxicity" refers to a state that causes damage to the heart muscle, such as heart failure, left ventricular failure, myocardial ischemia, myocardial infarction, QT prolongation, torsades de pointes, arrhythmia, pericarditis, myocarditis, bradycardia, hypertension, and thromboembolism. According to the present invention, cardiotoxicity can be caused by the direct or indirect action of a molecule or substance on the heart, such as a drug, alcohol, or heavy metal. Cardiotoxicity can be caused by, for example, at least one disease or disorder. Severe cardiotoxicity can lead to cardiomyopathy.

Mode for Carrying Out the Invention

[0077] Detailed Description Therefore, the present invention relates to the use of a nicotinamide mononucleotide derivative for the treatment of anti-cancer drug-induced toxicity, and the toxicity is preferably selected from cardiotoxicity, nephrotoxicity, hematotoxicity, hepatotoxicity, lymphotoxicity, gastrointestinal toxicity, cutaneous toxicity, reproductive toxicity, bone toxicity, genotoxicity, and bladder toxicity. In particular, the present invention relates to a nicotinamide mononucleotide derivative for use in the treatment of anti-cancer drug-induced toxicity in a subject that requires it.

[0078] Nicotinamide Mononucleotide Derivative In one embodiment, the nicotinamide mononucleotide derivative of the present invention is a compound of formula (I)

Chemical Formula

[0079] In one embodiment, in formula (I), X is selected from O, CH2, S, Se, CHF, CF2 and C=CH2; R1 is selected from H, azide, cyano, (C1-C8) alkyl, (C1-C8) thio-alkyl, (C1-C8) heteroalkyl and OR, where R is selected from H and (C1-C8) alkyl; R2, R3, R4 and R5 are independently selected from H, halogen, azide, cyano, hydroxyl, (C1-C 12 ) alkyl, (C1-C 12 ) thio-alkyl, (C1-C 12 ) heteroalkyl, (C1-C 12 ) haloalkyl and OR; where R is selected from H, (C1-C 12 ) alkyl, -C(O)(C1-C 12 ) alkyl, -C(O)NH(C1-C 12 ) alkyl, -C(O)O(C1-C ) 12 ) alkyl, -C(O)aryl, -C(O)(C1-C 12 ) alkylaryl, -C(O)NH(C1-C 12 ) alkyl-(C5-C 12 ) aryl, -C(O)O(C1-C 12 ) alkyl-(C5-C 12 ) aryl and -C(O)CHR AA NH2, where R AA is a side chain selected from the proteinogenic amino acids; R6 is selected from H, azide, cyano, (C1-C8) alkyl, (C1-C8) thio-alkyl, (C1-C8) heteroalkyl and OR, where R is selected from H and (C1-C8) alkyl; R7 is selected from H, P(O)R9R 10 P(S)R9R 10 and [ka] Selected from; here, R9 and R 10 These are independently OH, OR 11 NHR 13 , NR 13 R 14 , (C1~C8) alkyl, (C2~C8) alkenyl, (C2~C8) alkynyl, (C3~C 10 )Cycloalkyl, (C5~C 12 )Aaryl, (C5~C 12 )aryl-(C1~C8)alkyl, (C1~C8)alkyl-(C5~C 12 )aryl, (C1-C8) heteroalkyl, (C3-C8) heterocycloalkyl, (C5-C 12 ) Heteroaryl and NHCR α R α’ C(O)OR 12 Selected from; here - R 11 (C1~C 10 ) alkyl, (C3~C 10 )Cycloalkyl, (C5~C 12 )aryl, (C1~C 10 )alkyl-(C5~C 12 ) Aryl, substitution (C5~C 12 )aryl, (C1~C 10 ) Heteroalkyl, (C1~C 10 ) Haloalkyl, -(CH2) m C(O)(C1~C 15 ) Alkyl, -(CH2) m OC(O)(C1~C 15 ) Alkyl, -(CH2) m OC(O)O(C1~C 15 ) Alkyl, -(CH2) m SC(O)(C1~C 15 ) Alkyl, -(CH2) m C(O)O(C1~C 15 ) Alkyl, -(CH2) m C(O)O(C1~C 15)alkylaryl (where m is an integer selected from 1 to 8) and -P(O)(OH)OP(O)(OH)2, selected from internal or external counterions; - R 12 is hydrogen, (C1~C 10 )alkyl, (C2~C8)alkenyl, (C2~C8)alkynyl, (C1~C 10 ) Haloalkyl, (C3~C 10 )Cycloalkyl, (C3~C 10 )Cycloheteroalkyl, (C5~C 12 )aryl, (C1~C4)alkyl-(C5~C 12 )aryl and (C5~C 12 ) selected from heteroaryl groups; where the aryl or heteroaryl group is optionally substituted with one or two groups selected from halogens, trifluoromethyl, (C1-C6) alkyl, (C1-C6) alkoxy, and cyano groups; - R 13 and R 14 These are independently H, (C1~C8)alkyl and (C1~C8)alkyl-(C5~C 12 ) Selected from the arrow; - R α and R α’ Independently, hydrogen, (C1~C 10 ) Alkyl, (C2~C 10 ) Alkenil, (C2~C 10 ) Alkinyl, (C3~C 10 )Cycloalkyl, (C1~C 10 ) Thio-alkyl, (C1~C 10 ) Hydroxyalkyl, (C1~C 10 )alkyl-(C5~C 12 )aryl, (C5~C 12 )A side chain selected from aryl, -(CH2)3NHC(=NH)NH2, (1H-indole-3-yl)methyl, (1H-imidazole-4-yl)methyl and protein-constitutive or non-protein-constitutive amino acids; where the aryl group is hydroxyl, C1-C 10Optionally substituted with groups selected from alkyl, C1-C6 alkoxy, halogen, nitro, and cyano; or R9 and R 10 However, together with the phosphorus atom to which it bonds, it forms a 6-membered ring, where -R9-R 10 - represents -CH2-CH2-CHR- or -O-CH2-CH2-CHR-O-, where R is selected from hydrogen, (C5-C6)aryl and (C5-C6)heteroaryl groups; the aryl or heteroaryl group may be optionally substituted with one or two groups selected from halogens, trifluoromethyl, (C1-C6)alkyl, (C1-C6)alkoxy and cyano groups; X' is selected from O, CH2, S, Se, CHF, CF2, and C=CH2; R 1’ R is selected from H, azide, cyano, (C1-C8) alkyl, (C1-C8) thio-alkyl, (C1-C8) heteroalkyl and OR; where R is selected from H and (C1-C8) alkyl; R 2’ , R 3’ , R 4’ and R 5’ These are independently H, halogen, azide, cyano, hydroxyl, (C1~C 12 ) Alkyl, (C1~C 12 ) Thio-alkyl, (C1~C 12 ) Heteroalkyl, (C1~C 12 ) Selected from haloalkyl and OR; where R is H, (C1~C 12 )alkyl, -C(O)(C1~C 12 )alkyl, -C(O)NH(C1~C 12 )alkyl, -C(O)O(C1~C 12 )alkyl, -C(O)aryl, -C(O)(C1~C 12 )alkylaryl, -C(O)NH(C1~C 12 )alkyl-(C5~C 12 )aryl, -C(O)O(C1~C 12 )alkyl-(C5~C 12 )aryl and -C(O)CHR AASelected from NH2; here R AA These are side chains selected from the amino acids that make up the protein; R 6’ R is selected from H, azide, cyano, (C1-C8) alkyl, (C1-C8) thio-alkyl, (C1-C8) heteroalkyl, and OR; where R is selected from H and (C1-C8) alkyl; R 8’ H, OR, NHR 15’ , NR 15’ R 16’ NH-NHR 15’ Selected from SH, CN, N3 and halogen; where R 15’ and R 16’ These are independently selected from H, (C1-C8) alkyl, and (C1-C8) alkylaryl; Y' is selected from CH, CH2, C(CH3)2, and CCH3; n is an integer selected from 1 to 3; [ka] Y' represents a single or double bond; [ka] R 1’ Depending on its position, it represents either an alpha or beta anomer; R8 is H, OR, NHR 15 , NR 15 R 16 NH-NHR 15 Selected from SH, CN, N3 and halogen; where R 15 and R 16 These are independently selected from H, (C1-C8) alkyl, and (C1-C8) alkylaryl; Y is selected from CH, CH2, C(CH3)2, and CCH3; [ka] Y represents either a single or double bond; [ka] This represents either an alpha or beta anomer depending on the position of R1.

[0080] The nicotinamide mononucleotide derivative of the present invention may contain one or more charged atoms. In particular, the phosphate group, if present, may carry one or more charges, preferably one or more negative charges. Furthermore, the nitrogen atom of the pyridine moiety of the nicotinamide group may carry a positive charge of 1 if quaternized. The presence of one or more charged atoms in the nicotinamide mononucleotide derivative of the present invention depends on conditions recognized by those skilled in the art, particularly pH conditions.

[0081] According to one embodiment, X is selected from O, CH2, and S. In one embodiment, X is oxygen.

[0082] According to one embodiment, R1 is selected from hydrogen and OH. In one embodiment, R1 is hydrogen. In one embodiment, R1 is OH.

[0083] According to one embodiment, R2, R3, R4, and R5 are independently hydrogen, halogen, hydroxyl, C1-C 12 R is selected from alkyl and OR; where R is as described above herein. In a preferred embodiment, R2, R3, R4 and R5 are independently selected from hydrogen, hydroxyl and OR; where R is as described above herein. In a more preferred embodiment, R2, R3, R4 and R5 are independently selected from hydrogen and OH.

[0084] In one embodiment, R2 and R3 are the same. In one embodiment, R2 and R3 are the same and represent OH. In one embodiment, R2 and R3 are the same and represent hydrogen.

[0085] According to one embodiment, R2 and R3 are different. In a preferred embodiment, R2 is hydrogen and R3 is OH. In a more preferred embodiment, R2 is OH and R3 is hydrogen.

[0086] In one embodiment, R4 and R5 are the same. In one embodiment, R4 and R5 are the same and represent OH. In one embodiment, R4 and R5 are the same and represent hydrogen.

[0087] According to one embodiment, R4 and R5 are different. In a preferred embodiment, R4 is OH and R5 is hydrogen. In a more preferred embodiment, R4 is hydrogen and R5 is OH.

[0088] According to one embodiment, R3 and R4 are different. In one embodiment, R3 is OH and R4 is hydrogen. In one embodiment, R3 is hydrogen and R4 is OH.

[0089] In one embodiment, R3 and R4 are identical. In a preferred embodiment, R3 and R4 are identical and represent OH. In a more preferred embodiment, R3 and R4 are identical and represent hydrogen.

[0090] According to one embodiment, R2 and R5 are different. In one embodiment, R2 is hydrogen and R5 is OH. In one embodiment, R2 is OH and R5 is hydrogen.

[0091] In one embodiment, R2 and R5 are the same. In a preferred embodiment, R2 and R5 are the same and represent hydrogen. In a more preferred embodiment, R2 and R5 are the same and represent OH.

[0092] According to one embodiment, R6 is selected from hydrogen and OH. In one embodiment, R6 is OH. In a preferred embodiment, R6 is hydrogen.

[0093] In one embodiment, R1 and R6 are independently selected from hydrogen and OH. In another embodiment, both R1 and R6 are hydrogen atoms.

[0094] According to one embodiment, R7 is hydrogen, P(O)R9R 10 and [ka] Selected from.

[0095] According to one embodiment, R7 is hydrogen.

[0096] According to one embodiment, R7 is P(O)R9R 10 And here R9 and R 10 This is as described above in this specification. In a preferred embodiment, R7 is P(O)(OH)2.

[0097] According to one embodiment, R7 is [ka] And here R 1’ , R 2’ , R 3’ , R 4’ , R 5’ , R 6’ , R 8’ , R9, X', Y', n, [ka] [ka] and [ka] The properties of the compound of formula (I) are as described above in this specification.

[0098] According to a preferred embodiment, R7 is [ka] And here, X' is selected from O, CH2, and S, preferably X' is O; R 1’ is selected from hydrogen and OH, preferably R 1’ is hydrogen; R 2’ , R 3’ , R 4’ and R 5’ These are independently hydrogen, halogen, hydroxyl, (C1~C 12 ) Selected from alkyl and OR; where R is as described above herein, preferably R 2’ , R 3’ , R 4’ and R 5’ R is independently selected from hydrogen, hydroxyl, and OR; where R is as described above herein, and more preferably R 2’ , R 3’ , R 4’ and R 5’ These are independently selected from hydrogen and OH; R 6’ is selected from hydrogen and OH, preferably R 6’ is hydrogen; R 8’ These are H, OR, and NR 15’ R 16’ Selected from; here R 15’ and R 16’ This is as described above in this specification, preferably R 8’ NHR 15 And here R 15’ This is as stated above in this specification, and more preferably R 8’ It is NH2; Y' is selected from CH and CH2; n is an integer selected from 1 to 3; [ka] represents a junction; [ka] Y' represents a single or double bond; [ka] R 1’ Depending on its position, it represents either an alpha or beta anomer.

[0099] According to one embodiment, in formula (I), R7 is [ka] And here, X and X' are independently selected from O, CH2, and S, preferably X and X' are O; R1 and R 1’ These are independently selected from hydrogen and OH, preferably R1 and R 1’ is hydrogen; R2, R3, R4, R5, R 2’ , R 3’ , R 4’ and R 5’ These are independently hydrogen, halogen, hydroxyl, (C1~C 12 ) Selected from alkyl and OR; where R is as described above herein, preferably R2, R3, R4, R5, R 2’ , R 3’ , R 4’ and R 5’ R is independently selected from hydrogen, hydroxyl, and R; where R is as described above herein, more preferably R2, R3, R4, R5, R 2’ , R 3’ , R 4’ and R 5’ These are independently selected from hydrogen and OH; R6 and R 6’ These are independently selected from hydrogen and OH, preferably R6 and R 6’ is hydrogen; R8 and R 8’ These are H, OR, and NR independently. 15’ R 16’Selected from; here R 15’ and R 16’ These are as described above in this specification, preferably R8 and R 8’ NHR 15 And here R 15’ The above is as specified herein, and more preferably R8 and R 8’ It is NH2; Y and Y' are independently selected from CH and CH2; n is an integer selected from 1 to 3; [ka] represents a junction; [ka] Y and Y' represent single or double bonds; [ka] R1 and R 1’ Depending on its position, it represents either an alpha or beta anomer.

[0100] According to one embodiment, n is 1. According to one embodiment, n is 2. According to one embodiment, n is 3.

[0101] According to one embodiment, R8 is H, OR, and NR 15 R 16 Selected from; here R 15 and R 16 This is as described above in this specification. In a preferred embodiment, R8 is NHR 15 And here R 15 This is as described above in this specification. In one embodiment, R8 is NH2.

[0102] According to one embodiment, Y is CH or CH2. In one embodiment, Y is CH. In one embodiment, Y is CH2.

[0103] According to a preferred embodiment, the nicotinamide mononucleotide derivative used in the present invention is a compound of general formula (II): [ka] And, In the formula, R1, R2, R3, R4, R5, R6, R8, X, Y, [ka] and [ka] With respect to the compound of formula (I), it is as described above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0104] According to one embodiment, a preferred compound of general formula (II) is a compound of formula (II-1): [ka] And, In the formula, R1, R2, R3, R4, R5, R6, R8, Y, [ka] and [ka] With respect to the compound of formula (I), it is as described above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0105] According to one embodiment, a preferred compound of general formula (II) is a compound of formula (II-2): [ka] And, In the formula, R2, R3, R4, R5, R6, R8, Y, [ka] and [ka] With respect to the compound of formula (I), it is as described above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0106] According to one embodiment, a preferred compound of general formula (II) is a compound of formula (II-3): [ka] And, In the formula, R2, R5, R6, R8, Y, [ka] and [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0107] According to one embodiment, a preferred compound of general formula (II) is a compound of formula (II-4): [ka] And, In the formula, R6, R8, Y, [ka] and [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0108] According to one embodiment, a preferred compound of general formula (II) is a compound of formula (II-5): [ka] And, In the formula, R8, Y, [ka] and [ka] With respect to the compound of formula (I), it is as described above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0109] According to one embodiment, a preferred compound of general formula (II) is a compound of formula (II-6): [ka] And, In the formula, Y, [ka] and [ka] With respect to the compound of formula (I), it is as described above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0110] According to one embodiment, a preferred compound of general formula (II) is a compound of formula (II-7): [ka] And, During the ceremony, [ka] With respect to the compound of formula (I), it is as described above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0111] According to one embodiment, a preferred compound of general formula (II) is a compound of formula (II-8): [ka] And, During the ceremony, [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0112] According to another preferred embodiment, the nicotinamide mononucleotide derivative used in the present invention is a compound of general formula (III): [ka] And, In the formula, R1, R2, R3, R4, R5, R6, R8, X, Y, [ka] and [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0113] According to one embodiment, a preferred compound of general formula (III) is a compound of formula (III-1): [ka] And, In the formula, R1, R2, R3, R4, R5, R6, R8, Y, [ka] and [ka] With respect to the compound of formula (I), it is as described above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0114] According to one embodiment, a preferred compound of general formula (III) is a compound of formula (III-2): [ka] And, In the formula, R2, R3, R4, R5, R6, R8, Y, [ka] and [ka] With respect to the compound of formula (I), it is as described above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0115] According to one embodiment, a preferred compound of general formula (III) is a compound of formula (III-3): [ka] And, In the formula, R2, R5, R6, R8, Y, [ka] and [ka] With respect to the compound of formula (I), it is as described above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0116] According to one embodiment, a preferred compound of general formula (III) is a compound of formula (III-4): [ka] And, In the formula, R6, R8, Y, [ka] and [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0117] According to one embodiment, a preferred compound of general formula (III) is a compound of formula (III-5): [ka] And, In the formula, R8, Y, [ka] and [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0118] According to one embodiment, a preferred compound of general formula (III) is a compound of formula (III-6): [ka] And, In the formula, Y, [ka] and [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0119] According to one embodiment, a preferred compound of general formula (III) is a compound of formula (III-7): [ka] And, During the ceremony, [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0120] According to one embodiment, a preferred compound of general formula (III) is a compound of formula (III-8): [ka] And, During the ceremony, [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0121] According to another preferred embodiment, the nicotinamide mononucleotide derivative used in the present invention is a compound of general formula (IV): [ka] And, In the formula, R1, R 1’ , R2, R 2’ , R3, R 3’ , R4, R 4’ , R5, R5’ R6, R 6’ , R8, R 8’ , X, X', Y, Y', [ka] and [ka] With respect to the compound of formula (I), it is as described above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0122] According to one embodiment, a preferred compound of general formula (IV) is a compound of formula (IV-1): [ka] And, In the formula, R1, R 1’ , R2, R 2’ , R3, R 3’ , R4, R 4’ , R5, R 5’ , R6, R 6’ , R8, R 8’ , Y, Y', [ka] and [ka] With respect to the compound of formula (I), it is as described above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0123] According to one embodiment, a preferred compound of general formula (IV) is a compound of formula (IV-2): [ka] And, In the formula, R2, R 2’ , R3, R 3’ , R4, R 4’, R5, R 5’ R6, R 6’ , R8, R 8’ , Y, Y', [ka] and [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0124] According to one embodiment, a preferred compound of general formula (IV) is a compound of formula (IV-3): [ka] And, In the formula, R2, R 2’ , R5, R 5’ R6, R 6’ , R8, R 8’ , Y, Y', [ka] and [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0125] According to one embodiment, a preferred compound of general formula (IV) is a compound of formula (IV-4): [ka] And, In the formula, R6, R 6’ , R8, R 8’ , Y, Y', [ka] and [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0126] According to one embodiment, a preferred compound of general formula (IV) is a compound of formula (IV-5): [ka] And, In the formula, R6, R 6’ , R8, R 8’ , Y, Y', [ka] and [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0127] According to one embodiment, a preferred compound of general formula (IV) is a compound of formula (IV-6): [ka] And, In the formula, Y, Y', [ka] and [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0128] According to one embodiment, a preferred compound of general formula (IV) is a compound of formula (IV-7): [ka] And, During the ceremony, [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0129] According to one embodiment, a preferred compound of general formula (IV) is a compound of formula (IV-8): [ka] And, During the ceremony, [ka] With respect to the compound of formula (I), it is as stated above in this specification. A compound, or a pharmaceutically acceptable salt or solvate thereof.

[0130] According to one embodiment, the nicotinamide mononucleotide derivative used in the present invention is selected from compounds 001 to 014 in Table 1 below, as well as their pharmaceutically acceptable salts and solvates: [Table 2] TIFF0007842734000118.tif189162

[0131] According to one embodiment, preferred nicotinamide mononucleotide derivatives are compounds 001 to 014 or pharmaceutically acceptable salts or solvates thereof.

[0132] According to one embodiment, more preferred nicotinamide mononucleotide derivatives are compounds 001, 002, 009, 010, and 011 or their pharmaceutically acceptable salts or solvates.

[0133] According to one embodiment, a more preferred nicotinamide mononucleotide derivative is compound 001 and 002 or a pharmaceutically acceptable salt or solvate thereof.

[0134] According to another embodiment, more preferred nicotinamide mononucleotide derivatives are compounds 009, 010, and 011 or their pharmaceutically acceptable salts or solvates.

[0135] According to one embodiment, more preferred nicotinamide mononucleotide derivatives are compounds 002, 010, and 011 or pharmaceutically acceptable salts or solvates thereof.

[0136] All references to compounds of formula (I) and its subformulas include references to their salts, solvates, multicomponent complexes, and liquid crystals. All references to compounds represented by formula (I) and its subformulas include references to their polymorphs and crystal habits.

[0137] All references to compounds represented by formula (I) and its subformulas include references to their pharmaceutically acceptable prodrugs.

[0138] The nicotinamide mononucleotide derivative used in the present invention may be in the form of a pharmaceutical composition. In one embodiment, the pharmaceutical composition comprises the nicotinamide mononucleotide derivative as defined herein and at least one pharmaceutically acceptable carrier.

[0139] process In another aspect, the present invention relates to a method for preparing the compound of formula (I) described herein.

[0140] In particular, the compound of formula (I) can be prepared from substrates A to E as described below. Those skilled in the art will understand that these schemes are not limiting and that variations can be made without departing from the spirit and scope of the present invention.

[0141] According to one embodiment, the method comprises, in the first step, producing a phosphorodichloride of formula (B) by monophosphorylation of a compound of formula (A) in the presence of phosphoryl chloride and trialkyl phosphate: [ka] (In the formula, X, R1, R2, R3, R4, R5, R6, R8, Y, [ka] and [ka] (As stated above in this specification).

[0142] In the second step, the phosphorodichloride of formula (B) is hydrolyzed to produce the phosphate of formula (C): [ka] (In the formula, X, R1, R2, R3, R4, R5, R6, R7, R8, Y, [ka] and [ka] (As stated above in this specification).

[0143] In an alternative embodiment, in equation (I), R7 is [ka] If so, the phosphate compound of formula (C) obtained in the second step is then obtained as formula (B') as described in the first step: [ka] (In the formula, R 1’ , R 2’ , R 3’ , R 4’ , R 5’ , R 6’ , R 8’ , X', Y', [ka] and [ka] It reacts with the phosphorodichloride compound (as described above in this specification) and is subsequently hydrolyzed to produce the compound of formula (I).

[0144] According to one embodiment, the compound of formula (A) is synthesized using various methods known to those skilled in the art.

[0145] According to one embodiment, the compound of formula (A), referred to as the compound of formula (Aa), where Y is CH, is synthesized by reacting the pentose of formula (D) with the nitrogen derivative of formula (E) to yield the compound of formula (A-1), which is then selectively deprotected to give the compound of formula (Aa): [ka] (In the formula, X, R1, R2, R3, R4, R5, R6, R8, Y, [ka] and [ka] (As stated above in this specification, R is a protecting group).

[0146] According to one embodiment, R is a suitable protecting group known to those skilled in the art. In one embodiment, the protecting group is selected from triarylmethyl and silyl groups. Non-limiting examples of triarylmethyl include trityl, monomethoxythyritol, 4,4'-dimethoxytrityl, and 4,4',4''-trimethoxytrityl. Non-limiting examples of silyl groups include trimethylsilyl, tert-butyldimethylsilyl, triisopropylsilyl, tert-butyldiphenylsilyl, triisopropylsilyloxymethyl, and [2-(trimethylsilyl)ethoxy]methyl.

[0147] According to one embodiment, any hydroxyl group bonded to a pentose is protected by a suitable protecting group known to those skilled in the art.

[0148] The selection and replacement of protecting groups is the responsibility of those skilled in the art. Protecting groups can also be removed by methods well known to those skilled in the art, for example, by an acid (e.g., a mineral acid or an organic acid), a base, or a fluoride source.

[0149] According to a preferred embodiment, the nitrogen nicotinamide of formula (E) is coupled to the compound of formula (D) in the presence of a Lewis acid to yield the compound of formula (A-1). Non-limiting examples of Lewis acids include TMSOTf, BF3.OEt2, TiCl4, and FeCl3.

[0150] According to one embodiment, the method of the present invention further reduces a compound of formula (Aa) by various methods well known to those skilled in the art, where Y is CH2, and X, R1, R2, R3, R4, R5, R6, R8, [ka] and [ka] However, it includes the step of yielding a compound of formula (Ab), as defined earlier.

[0151] According to a specific embodiment, the present invention relates to a method for preparing compounds 001, 003, 005, 007, and 009.

[0152] In the first step, the nicotinamide of formula (Ei) is coupled to the ribose tetraacetate of formula (Di) in the presence of a Lewis acid to yield the compound of formula (Ali): [ka]

[0153] In the second step, the compound of formula (A-1-i) is subjected to ammoniacal treatment to yield compound 005: [ka]

[0154] In the third step, monophosphorylation of compound 005 in the presence of phosphoryl chloride and trialkyl phosphate yields a phosphorodichloride of formula (Bi): [ka]

[0155] In the fourth step, the phosphorodichloride of formula (Bi) is hydrolyzed to produce compound 001: [ka]

[0156] Alternatively, in the fifth step, the phosphate compound 001 obtained in the fourth step then reacts with the phosphorodichloride of formula (Bi) obtained as described in the third step to give compound 009.

[0157] According to one embodiment, the step of reducing compound 005 A-2 is performed to obtain compound 007.

[0158] The compound of formula 007 is then monophosphorylated as described in the fourth step and hydrolyzed to compound 003.

[0159] The above method for preparing compounds 001, 003, 005, and 007 is given by formula (D-ii): [ka] By using a suitable starting ribosol tetraacetate, the synthesis of compounds 002, 004, 006, and 008 can be easily adapted.

[0160] The above method for preparing dimer compound 009 can be easily adapted to the synthesis of dimer compounds 010-014 by using the corresponding appropriate phosphorodichloride and phosphate intermediates.

[0161] Management of anti-cancer drug-induced toxicity As described above, there is an unmet need for the treatment of drug-induced toxicity, particularly anti-cancer drug-induced toxicity. Therefore, an object of the present invention is to provide treatment for drug-induced toxicity, particularly anti-cancer drug-induced toxicity, to subjects that require it. In particular, the present invention relates to nicotinamide mononucleotide derivatives as defined above herein for use in the treatment of drug-induced toxicity, particularly anti-cancer drug-induced toxicity, in subjects that require it.

[0162] Drug-induced toxicity According to one embodiment, toxicity is caused by at least one drug of a class selected from anticancer drugs; antidepressants; antiretroviral drugs; antidiabetic drugs; antihypertensive drugs; antiarrhythmic drugs; CNS stimulants; antimalarial drugs; immunosuppressants such as cyclosporine; antifungal agents such as ketoconazole; cytokines; interferons; anabolic steroids; adrenergic stimulants such as ephedrine; neuromodulators such as catecholamines; COX inhibitors such as NAISD; and mixtures thereof.

[0163] "Antineoplastic drugs" or "antineoplastic agents" refer to drugs used to treat cancer. They may also be called chemotherapeutic agents.

[0164] Non-exclusive examples of anti-cancer drugs include: - Anthracyclines, such as doxorubicin, bleomycin, actinomycin D, daunorubicin, epirubicin, idarubicin, mitomycin, mitoxantrone, plicamycin, and barurubicin; - Alkylating agents, such as altretamine, bendamustine, busulfan, carmustine, chlorambucil, cyclophosphamide, dacarbazine, ifosphamide, lomustine, mechloretamine, melphalan, procarbazine, streptozocin, temozolomide, thiotepa, trabectedin, platinum-coordinated complexes, carboplatin, cisplatin, and oxaliplatin; - Taxanes, such as cabazitaxel, docetaxel, and paclitaxel; - Topoisomerase inhibitors, e.g., etoposide, irinotecan, teniposide, topotecan; - Antimetabolites: e.g., folate antagonists: methotrexate, premetrexed, pralatrexate, and trimethrexate; purine analogs: azathioprine, cladribine, fludarabine, mercaptopurine, and thioguanine; and pyrimidine analogs: azacitidine, capecitabine, cytarabine, decitabine, phloxuridine, 5-fluorouracil, gemcitabine, and trifluridine / tipracil; - Protein kinase inhibitors, e.g., abemaciclib, acalabrutinib, afatinib, alectinib, axitinib, binimetinib, bortezomib, bosutinib, brigatinib, cabozantinib, carfilzomib, ceritinib, cobimetinib, copanlisib, crizotinib, dabrafenib, dacomitinib, dasatinib, duvelisib, enasidenib, encorafenib, erlotinib, gefitinib, gilteritinib, glassegib, ibrutinib, idelari Sibu, imatinib, ivosidenib, ixazomib, lapatinib, lalotrectinib, lenvatinib, lorlatinib, midostaurin, neratinib, nilotinib, niraparib, olaparib, osimertinib, palbociclib, pazopanib, ponatinib, regorafenib, ribociclib, rucaparib, ruxolitinib, sonidegib, sorafenib, sunitinib, talazoparib, trametinib, vandetanib, vemurafenib, and bismodegib; - Bio-response modifiers, such as aldethleukin (IL-2), denileukin difuticox, and interferon gamma; - Histone deacetylase inhibitors, such as bellinostat, panobinostat, romidepsin, and vorinostat. - Hormones, such as antiandrogens: abiraterone, apalutamide, bicalutamide, cyproterone, enzalutamide, flutamide, and nilutamide; antiestrogens (including aromatase inhibitors): anastrozole, exemestane, fulvestrant, letrozole, raloxifene, tamoxifen, and toremifene; gonadotropin-releasing hormone analogs: degarelix, goserelin, histrelin, leuprotide, and triptorelin; and peptide hormones: lanreotide, octreotide, and pasireotide. - Monoclonal antibodies, such as alemtuzumab, atezolizumab, avelumab, bevacizumab, blinatumomab, brentuximab, semiprimab, cetuximab, daratumumab, dinutuximab, durvalumab, elotuzumab, gemtuzumab, inotuzumab, ozogamicin, ipilimumab, mogamulizumab, moxetumomab, pasdotox, necitumumab, nivolumab, ofatumumab, olaratumumab, panitumumab, pembrolizumab, pertuzumab, ramucirumab, rituximab, tocitumomab, and trastuzumab. - Vinca alkaloids, such as vinblastine, vincristine, vinorelbine; and - Other anticancer drugs, such as mitomycin, bortezomib, estramustine, ixabepyrone, asparaginase (pegaspargase), bexarotene, eribulin, everolimus, hydroxyurea, ixabepyrone, lenalidomide, mitotane, omasetaxin, pomalidomide, taglaxofusp, tetrotristat, temsirolimus, thalidomide, and venetoclax. These are some examples.

[0165] Non-specific examples of antidepressants include: - Tricyclic antidepressants, such as amitriptyline, clomipramine, amoxapine, desipramine, doxepin, imipramine, nortriptyline, protriptyline, and trimipramine; - Tetracyclic antidepressants, such as amoxapine, maprotiline, mianserin, mirtazapine, and septilin; - Selective serotonin reuptake inhibitors, such as citalopram, escitalopram, fluoxetine, fluvoxamine, paroxetine, and sertraline; - Serotonin-norepinephrine reuptake inhibitors, e.g., desvenlafaxine, duloxetine, levomirnacipran, milnacipran, and venlafaxine; - Serotonin modulators and stimulants, e.g., virazodone and vortioxetine - Serotonin antagonists and reuptake inhibitors, such as nefazodone and trazodone; - Norepinephrine reuptake inhibitors, such as atomoxetine, reboxetine, teniroxazine, and biloxazine; - Norepinephrine-dopamine reuptake inhibitors, e.g., bupropion; - Monoamine oxidase inhibitors, such as isocarboxazide, phenelzine, and tranylcypromine, These are some examples.

[0166] Non-exclusive examples of antiretroviral drugs include nucleoside reverse transcriptase inhibitors such as zidovudine.

[0167] Non-specific examples of antihypertensive drugs include: - Calcium channel blockers of a class selected from dihydropyridines such as nifedipine; phenylethylamines such as verapamil; and benzothiazepines such as zirlithiazem; - Beta-adrenoceptor antagonists such as isoproterenol, These are some examples.

[0168] Non-exclusive examples of CNS stimulants include methylphenidate, amphetamine, and methamphetamine.

[0169] According to a preferred embodiment, the drug-induced toxicity is that of an anti-cancer drug.

[0170] Accordingly, the present invention relates to the above-mentioned nicotinamide mononucleotide derivatives for use in the treatment of anticancer drug-induced toxicity.

[0171] According to one embodiment, toxicity is caused by at least one anti-cancer drug selected from anthracyclines, alkylating agents, taxanes, antimetabolites, monoclonal antibodies, tyrosine kinase inhibitors, and mixtures thereof. According to one embodiment, anti-cancer drug-induced toxicity is caused by at least one drug selected from anthracyclines, alkylating agents, taxanes, antimetabolites, bioresponse modifiers, histone deacetylase inhibitors, hormones, vinca alkaloids, topoisomerase inhibitors, monoclonal antibodies, and tyrosine kinase inhibitors, and mixtures thereof.

[0172] According to a preferred embodiment, the anti-cancer drug-induced toxicity is anthracycline-induced toxicity caused by at least one agent selected from doxorubicin, daunorubicin, epirubicin, idarubicin, mitoxantrone, and barurubicin.

[0173] According to a more preferred embodiment, the anti-cancer drug-induced toxicity is anthracycline-induced toxicity caused by doxorubicin.

[0174] Therefore, according to one embodiment, the above nicotinamide mononucleotide derivative is for use in the treatment of anticancer drug-induced toxicity. According to a preferred embodiment, the above nicotinamide mononucleotide derivative is for use in the treatment of anthracycline-induced toxicity. According to a more preferred embodiment, the above nicotinamide mononucleotide derivative is for use in the treatment of doxorubicin-induced toxicity.

[0175] According to one embodiment, the toxicity described herein is acute toxicity. According to one embodiment, the toxicity described herein is chronic toxicity.

[0176] According to one embodiment, the above-mentioned toxicity in this specification is selected from cardiotoxicity, nephrotoxicity, neurotoxicity, hematological toxicity, hepatotoxicity, lymphotoxicity, gastrointestinal toxicity, cutaneous toxicity, metabolic toxicity, ototoxicity, reproductive toxicity, osteotoxicity, genotoxicity, and bladder toxicity. According to one embodiment, the above-mentioned toxicity in this specification is selected from cardiotoxicity, nephrotoxicity, hematological toxicity, hepatotoxicity, lymphotoxicity, gastrointestinal toxicity, cutaneous toxicity, metabolic toxicity, reproductive toxicity, osteotoxicity, genotoxicity, and bladder toxicity.

[0177] In one embodiment, the toxicity is not neurotoxic. In one embodiment, the toxicity is not ototoxic.

[0178] According to a preferred embodiment, the toxicity is cardiotoxic.

[0179] According to one embodiment, cardiotoxicity is selected from heart failure, left ventricular failure, myocardial ischemia, myocardial infarction, hypokalemia, QT prolongation, torsades de pointes, arrhythmia, pericarditis, myocarditis, bradycardia, hypertension, and thromboembolism.

[0180] According to one embodiment, cardiotoxicity is not due to arrhythmia.

[0181] The present invention also relates to a pharmaceutical composition comprising at least one compound for use in the present invention as described herein, and at least one pharmaceutically acceptable carrier for use in the toxic treatment described herein.

[0182] Subjects requiring a response Preferably, the subject requiring therapeutic and / or preventive treatment is a warm-blooded animal, more preferably a human. According to one embodiment, the subject is male. According to one embodiment, the subject is female.

[0183] According to one embodiment, the subjects are adults, i.e., those over 18 years of age. According to one embodiment, the subjects are children, i.e., those under 18 years of age. According to one embodiment, the subjects are infants, i.e., those between 1 month and 2 years of age. According to one embodiment, the subjects are newborns, i.e., those under 1 month of age.

[0184] In a preferred embodiment, the subjects are over 50, 55, 60, 65, 70, 75, 80, 85, 90, or 95 years of age. In one embodiment, the subjects are over 65, 70, 75, 80, 85, 90, or 95 years of age.

[0185] According to another preferred embodiment, the target age is 20, 15, 10, or under 5 years. In one embodiment, the target age is 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, or under 2 years.

[0186] According to one embodiment, a subject is being administered or is scheduled to be administered a drug that is likely to induce the above-mentioned toxicity for the treatment of a condition in which the subject requires it. In particular, the subject is being administered or is scheduled to be administered the above-mentioned anti-cancer drug.

[0187] According to one embodiment, the target is 100 mg / m². 2 Exceeding 200 mg / m² 2 Exceeding 300 mg / m² 2 Exceeding 400 mg / m² 2 Exceeding 500 mg / m² 2 Exceeding 600 mg / m² 2 Exceeding 700 mg / m² 2 Exceeding 800 mg / m² 2 Exceeding 900 mg / m² 2 If it exceeds 1000 mg / m², or 1000 mg / m² 2 The subject has been or is scheduled to be administered at least one drug that is likely to induce the above toxicity in a cumulative dose exceeding, preferably an annual cumulative dose. In one embodiment, the subject required is 400 mg / m². 2 Exceeding 500 mg / m² 2 Exceeding 600 mg / m² 2 Exceeding 700 mg / m² 2 Exceeding 800 mg / m² 2 Exceeding 900 mg / m² 2 If it exceeds 1000 mg / m², or if it is 1000 mg / m² 2The patient is receiving treatment with at least one of the above-mentioned drugs in a cumulative dose exceeding a certain amount.

[0188] According to one embodiment, the subject is not suffering from any underlying pathological condition.

[0189] According to one embodiment, the subject is at risk of developing the above-mentioned toxicity. According to one embodiment, the subject is at risk of developing toxicity caused by at least one of the above-mentioned drugs. According to one embodiment, the subject is at risk of developing toxicity caused by at least one anti-cancer drug. According to one embodiment, the subject is at risk of developing toxicity caused by at least one anthracycline drug. According to one embodiment, the subject is at risk of developing toxicity caused by doxorubicin.

[0190] According to one embodiment, the subject is at risk of developing cardiotoxicity. According to one embodiment, the subject is at risk of developing cardiotoxicity caused by at least one of the above-mentioned drugs. According to one embodiment, the subject is at risk of developing cardiotoxicity caused by at least one anti-cancer drug. According to one embodiment, the subject is at risk of developing cardiotoxicity caused by at least one anthracycline drug. According to one embodiment, the subject is at risk of developing cardiotoxicity caused by doxorubicin.

[0191] According to one embodiment, the subject has at least one risk factor that may lead to an increased risk of developing toxicity, particularly drug-induced toxicity, namely, a pre-existing disease, condition, habit, or behavior.

[0192] According to one embodiment, the subjects present with at least one risk factor selected from active chemotherapy, combined radiotherapy, or cardiac irradiation, combined procedures, previous procedures such as coronary artery bypass grafting, angioplasty, or vascular stenting, a history of left ventricular dysfunction, myocardial infarction, angina pectoris, congestive heart failure, or cardiovascular complications, genetic predisposition, autoimmune disease or condition, cardiovascular disease or condition, active smoking, chronic passive smoking (also known as environmental exposure smoking), alcoholism, drug dependence, obesity (BMI > 35), cystic fibrosis, diabetes mellitus, dyslipidemia, hypertension, renal failure, immunodeficiency, immunosuppression, immunotherapy or antibody treatment for cancer, active infection with hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV), pregnancy, particularly pregnant women with significant heart disease (either congenital or acquired), pulmonary hypertension, lack of exercise, patients under 4 years of age, or patients over 65 years of age.

[0193] According to one embodiment, the subject develops the above-mentioned toxicity. According to one embodiment, the subject develops toxicity induced by at least one of the above-mentioned drugs. According to one embodiment, the subject develops toxicity caused by at least one anti-cancer drug. According to one embodiment, the subject develops toxicity caused by at least one anthracycline drug. According to one embodiment, the subject develops toxicity caused by doxorubicin.

[0194] According to one embodiment, the subject suffers from at least one complication, namely a disease or condition that coexists with toxicity.

[0195] According to one embodiment, the subject presents with at least one complication selected from hypertension, coronary artery disease, atrial fibrillation, diabetes mellitus, chronic renal failure, cerebrovascular disease, anemia, and obesity.

[0196] According to one embodiment, subjects requiring therapeutic and / or preventive measures according to the present invention are diagnosed by healthcare professionals. For example, cardiotoxicity is diagnosed by any tests performed routinely in a healthcare setting, including electrocardiograms, aimed at identifying a total or partial reduction in systolic function, i.e., a reduction in left ventricular ejection fraction to a value greater than 10% but less than 50% is generally used as a determinant threshold for defining cardiotoxicity.

[0197] Alternatively, the severity of cardiotoxicity may be assessed based on the measurement of the mean resting-corrected QT interval obtained from three consecutive ECGs, as follows: - QTc less than 330ms = very short QT; - QTc = QT shortening between 330ms and 370ms; - QTc = normal QT between 370ms and 400ms; - Possibility of QTc=QT extension between 400ms and 460ms; - QTc = QT extension between 460ms and 470ms; and - QTc exceeding 470ms = very long QT.

[0198] In one embodiment, the subject exhibits a QT of less than 330 ms. In one embodiment, the subject exhibits a QTc between 330 ms and 370 ms. In one embodiment, the subject exhibits a QTc between 400 ms and 460 ms. In one embodiment, the subject exhibits a QTc between 460 ms and 470 ms. In one embodiment, the subject exhibits a QTc greater than 470 ms.

[0199] Based on their clinical symptoms, cardiotoxic events can be classified into three types: (1) Characterized by acute cardiotoxicity, i.e., suppression of myocardial contractility that occurs during or immediately after the procedure and may recur within one week if the chemotherapy treatment is discontinued; (2) Early-onset chronic progressive cardiotoxicity, characterized by systolic or diastolic ventricular dysfunction within one year after completion of chemotherapy; (3) Subsequent chronic progressive cardiotoxicity, characterized by cardiac failure following a latent period of more than one year after the completion of chemotherapy.

[0200] According to one embodiment, the subject suffers from acute cardiotoxicity. According to one embodiment, the subject suffers from early-onset chronic progressive cardiotoxicity. According to one embodiment, the subject suffers from late-onset chronic progressive cardiotoxicity.

[0201] Therapeutic effect According to one embodiment, the use of the above-mentioned nicotinamide mononucleotide derivative prevents, reduces, alleviates, and / or slows down (reduces) one or more symptoms of drug-induced toxicity, particularly antineoplastic drug-induced toxicity, more specifically antineoplastic drug-induced cardiotoxicity.

[0202] According to one embodiment, the compound for use described above reduces the risk of the subject experiencing toxicity induced by at least one of the above drugs by at least 1% to 10%. In one embodiment, the compound for use described above reduces the risk of toxicity by at least 11% to 20%. In one embodiment, the compound for use described above reduces the risk of toxicity by at least 21% to 30%. In one embodiment, the compound for use described above reduces the risk of toxicity by at least 31% to 40%. In one embodiment, the compound for use described above reduces the risk of toxicity by at least 41% to 50%. In one embodiment, the compound for use described above reduces the risk of toxicity by at least 51% to 60%. In one embodiment, the compound for use described above reduces the risk of toxicity by at least 61% to 70%. In one embodiment, the compound for use described above reduces the risk of toxicity by at least 71% to 80%. In one embodiment, the compound for use described above reduces the risk of toxicity by at least 81% to 90%. In one embodiment, the compound for use described above reduces the risk of toxicity by at least 91% to 100%.

[0203] Method of administration The compounds of the present invention described herein may be administered orally, parenterally (e.g., intramuscular, intraperitoneal, intravenous, ICV, intracisional injection or infusion, subcutaneous injection, or implantation), by inhalation spray, or via nasal, rectal, sublingual, or topical administration routes, and may be formulated alone or together in appropriate dosage unit formulations containing conventional non-toxic, pharmaceutically acceptable carriers, adjuvants, and vehicles suitable for each administration route. In addition to the treatment of warm-blooded animals such as mice, rats, horses, cattle, sheep, dogs, cats, and monkeys, the compounds of the present invention are effective for use in humans. Pharmaceutical compositions for the administration of the compounds of the present invention may be presented in dosage unit formulations or may be prepared by any method well known in the pharmaceutical art. All methods involve the step of associating the active ingredient with carriers constituting one or more auxiliary components. Generally, pharmaceutical compositions are prepared by homogeneously and thoroughly associating the active ingredient with a liquid carrier or a micronized solid carrier or both, and then, if necessary, forming the product into a desired formulation. In a pharmaceutical composition, the active compound of interest is present in an amount sufficient to produce the desired effect on a process or disease state. As used herein, the term “composition” includes products containing specified amounts of specified components, and any products obtained directly or indirectly from specified amounts of combinations of specified components.

[0204] The pharmaceutical composition containing the active ingredient may be in a form suitable for oral use, such as tablets, lozenges, watery or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.

[0205] Compositions intended for oral use may be prepared according to any method known in the art for the manufacture of pharmaceutical compositions, and such compositions may contain one or more activators selected from the group consisting of sweeteners, flavoring agents, colorants, and preservatives in order to provide a pharmaceutically refined and palatable preparation. Tablets contain an active ingredient mixed with non-toxic, pharmaceutically acceptable excipients suitable for the manufacture of tablets. These excipients may be inert diluents, e.g., calcium carbonate, sodium carbonate, lactose, calcium phosphate, or sodium phosphate; granulating and disintegrating agents, e.g., corn starch or arginine; binders, e.g., starch, gelatin, or gum arabic; and lubricants, e.g., magnesium stearate, stearic acid, or talc. Tablets may be uncoated, or they may be coated by known techniques that delay disintegration and absorption in the gastrointestinal tract, thereby providing a sustained effect over a longer period. For example, delaying agents such as glyceryl monostearate or glyceryl distearate may be used. They may be coated by the techniques described in U.S. Patents 4,256,108; 4,166,452; and 4,265,874 for forming permeable therapeutic tablets for controlled release. Formulations for oral use may also be presented as hard gelatin capsules in which the active ingredient is mixed with an inert solid diluent, such as calcium carbonate, calcium phosphate, or kaolin, or as soft gelatin capsules in which the active ingredient is mixed with water or an oily medium, such as peanut oil, liquid paraffin, or olive oil.

[0206] The aqueous suspension contains an active material mixed with an excipient suitable for the preparation of the aqueous suspension. Such excipients may be suspending agents, such as sodium carboxymethylcellulose, methylcellulose, hydroxypropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, tragacanth gum, and gum arabic, and the dispersing or wetting agent may be a naturally occurring phosphatide, such as lecithin, or a condensation product of an alkylene oxide and a fatty acid, such as polyoxyethylene stearate, or a condensation product of an ethylene oxide and a long-chain fatty alcohol, such as heptadecaethyleneoxycetanol, or a condensation product of an ethylene oxide and a partial ester derived from a fatty acid and hexitol, such as polyoxyethylene sorbitol monooleate, or a condensation product of an ethylene oxide and a partial ester derived from a fatty acid and hexitol anhydride, such as polyethylene sorbitan monooleate. Aqueous suspensions may contain one or more preservatives, ethyl or n-propyl, p-hydroxybenzoate, one or more colorants, one or more flavorings, and one or more sweeteners such as sucrose or saccharin. Oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, such as peanut oil, olive oil, sesame oil, or coconut oil, or in a mineral oil such as liquid paraffin. Oily suspensions may contain thickeners, such as beeswax, hard paraffin, or cetyl alcohol. Sweeteners such as the above-mentioned sweeteners and flavorings may be added to provide an oral preparation with a pleasant mouthfeel. These compositions may be preserved by the addition of antioxidants such as ascorbic acid. Dispersible powders and granules suitable for preparing aqueous suspensions by adding water provide the active ingredient mixed with a dispersing or wetting agent, a suspending agent, and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, such as sweeteners, flavorings, and colorings, may also be present.

[0207] Syrups and elixirs may be formulated with sweeteners, such as glycerol, propylene glycol, sorbitol, or sucrose. Such formulations may also contain lubricants, preservatives, flavorings, and colorings.

[0208] The pharmaceutical composition may be in the form of a sterile, injectable aqueous or oily suspension. This suspension may be formulated according to the knowledge of the art using the appropriate dispersants or wetting agents and suspending agents mentioned above. The sterile, injectable preparation may also be a sterile, injectable solution or suspension in a diluent or solvent acceptable for non-toxic parenteral administration, such as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be used are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile non-volatile oils have conventionally been used as solvents or suspensions. Any non-irritating non-volatile oil, including synthetic mono or diglycerides, may be used for this purpose. In addition, fatty acids such as oleic acid are utilized in the preparation of injectable preparations. The compounds of the present invention may also be administered in the form of suppositories for rectal administration of the drug. These compositions may be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore melts in the rectum to release the drug. Such materials are cocoa butter and polyethylene glycol. For topical use, creams, ointments, jellies, solutions, or suspensions containing the compound of the present invention can be used (for the purposes of this application, examples of topical applications would include mouthwashes and gargles).

[0209] Administration regimen In the treatment of toxicity, preferably cardiotoxicity, appropriate dose levels for the nicotinamide mononucleotide derivative of the present invention will generally be about 0.01 to 500 mg / kg patient body weight / day, which can be administered in single or multiple doses. Preferably, dose levels will be about 0.1 to about 350 mg / kg / day; more preferably, about 0.5 to about 100 mg / kg / day. Appropriate dose levels may be about 0.01 to 250 mg / kg / day, about 0.05 to 100 mg / kg / day, or about 0.1 to 50 mg / kg / day. Within this range, doses may be 0.05 to 0.5, 0.5 to 5, or 5 to 50 mg / kg / day. For oral administration, the composition is provided in the form of tablets containing preferably 1.0 to 1000 milligrams of the active ingredient, particularly 1.0, 5.0, 10.0, 15.0, 20.0, 25.0, 50.0, 75.0, 100.0, 150.0, 200.0, 250.0, 300.0, 400.0, 500.0, 600.0, 750.0, 800.0, 900.0, and 1000.0 milligrams of the active ingredient, in order to adjust the dosage to suit the symptoms of the patient being treated.

[0210] According to one embodiment, a subject requiring it is treated with at least one of the above nicotinamide mononucleotide derivatives in a cumulative dose exceeding 100 mg / kg, 200 mg / kg, 300 mg / kg, 400 mg / kg, 500 mg / kg, 600 mg / kg, 700 mg / kg, 800 mg / kg, 900 mg / kg, 1000 mg / kg, 2500 mg / kg, or 5000 mg / kg, preferably an annual cumulative dose.

[0211] Nicotinamide mononucleotide derivatives may be administered in regimens of 1 to 4 times per day, preferably 1, 2, or 3 times per day. However, the specific dose level and frequency of administration for any particular patient may vary and will depend on various factors, including the activity of the specific compound used, its metabolic stability and duration of action, age, weight, overall health, sex, diet, mode and frequency of administration, frequency of excretion, concomitant drug use, severity of a particular condition, and the treatment the host is receiving.

[0212] Monotherapy / Combination therapy The nicotinamide mononucleotide derivatives of the present invention may be used as monotherapy or in combination therapy in subjects requiring therapeutic and / or preventive treatment. Accordingly, according to the first embodiment, the nicotinamide mononucleotide derivatives for use of the present invention are administered to the subject without any other active ingredients. According to the second embodiment, the nicotinamide mononucleotide derivatives for use of the present invention are administered to the subject in combination with at least one other active ingredient.

[0213] In one embodiment, the compound is administered to a subject sequentially, simultaneously, and / or separately from other active ingredients.

[0214] In one embodiment, other active ingredients include natural extracts; anti-cancer agents; antidepressants; antiretroviral agents; beta-blockers; antidiabetic agents; diuretics; antihypertensive agents; antiarrhythmic agents; CNS stimulants; antimalarial agents; immunosuppressants; antifungal agents; cytokines; interferons; anabolic steroids; adrenergic stimulants; neuromodulators; COX inhibitors; angiotensin-converting enzyme inhibitors; angiotensin receptor blockers; lanolazine; metformin; and electrocorticoid receptor antagonists. The following are selected: hydroxymethylglutaryl coenzyme A reductase inhibitors; antioxidants such as quercetin's self-nanoemulsifying formulations; Q10 coenzyme; vitamin E; L-carnitine; steroids; cyclosporine; mycophenolate mofetil; anti-TNF drugs such as influximab or etanercept; anti-IL1 such as Sraninka; anti-PGF such as Gleevec; anti-CD20 such as rituximab; maltol; PTEN modifiers; nobiletin; pyrroloquinoline quinone; and urolithin.

[0215] In one embodiment, other active ingredients include anti-cancer drugs; antidepressants; antiretroviral drugs; beta-blockers; antidiabetic drugs; diuretics; antihypertensive drugs; antiarrhythmic drugs; CNS stimulants; antimalarial drugs; immunosuppressants; antifungal agents; cytokines; interferons; anabolic steroids; adrenergic stimulants; neuromodulators; COX inhibitors; angiotensin-converting enzyme inhibitors; angiotensin receptor blockers; lanolazine; metformin; electrocorticoid receptor antagonists; and hydrochloride. The following are selected: roxymethylglutaryl coenzyme A reductase inhibitors; antioxidants such as quercetin's self-nanoemulsifying formulations; Q10 coenzyme; vitamin E; L-carnitine; steroids; cyclosporine; mycophenolate mofetil; anti-TNF drugs such as influximab or etanercept; anti-IL1 such as Sraninka; anti-PGF such as Gleevec; anti-CD20 such as rituximab; maltol; PTEN modifiers; nobiletin; pyrroloquinoline quinone; and urolithin.

[0216] In one embodiment, other active ingredients are, for example, glycoprotein extracts from species such as Trametes versicolor, Lion's Mane, Maitake mushroom, Milk Thistle, Artichoke, Turmeric, Dandelion, Rumex japonicus, Beetroot, and Ginger; terpenoid extracts containing pentacyclic triterpenes such as betulin, pentacyclic triterpene metabolites such as betulinic acid, transpyroin, losenolactone, sesquiterpenes, and erinasine; flavonoid extracts containing flavones, flavonols, flavanones, flavanols, bioflavonoids, or isoflavonoids; polysaccharide extracts containing PSP, PSK, CVG, HPB-3, and H6PC20; or natural extracts such as polycyclic aromatic molecules such as hericerine and hericenone.

[0217] According to one embodiment, the pharmaceutical composition of the present invention further comprises at least another active ingredient. According to one embodiment, the pharmaceutical composition for use of the present invention comprises at least one compound for use of the present invention, plus at least one additional active ingredient, such as natural extracts; anti-cancer agents; antidepressants; antiretroviral agents; beta-blockers; antidiabetic agents; diuretics; antihypertensive agents; antiarrhythmic agents; CNS stimulants; antimalarial agents; immunosuppressants; antifungal agents; cytokines; interferons; anabolic steroids; adrenergic stimulants; neuromodulators; COX inhibitors; angiotensin-converting enzyme inhibitors; angiotensin receptor blockers; lanolazine; methopho The active ingredients include Lumin; electrolyte corticosteroid receptor antagonists; hydroxymethylglutaryl coenzyme A reductase inhibitors; antioxidants such as quercetin's self-nanoemulsified formulations; Q10 coenzyme; vitamin E; L-carnitine; steroids; cyclosporine; mycophenolate mofetil; anti-TNF drugs such as influximab or etanercept; anti-IL1 such as Sraninka; anti-PGF such as Gleevec; anti-CD20 such as rituximab; maltol; PTEN modifiers; nobiletin; pyrroloquinoline quinone; and urolithin.

[0218] According to one embodiment, the pharmaceutical composition further comprises at least one other active ingredient selected from natural extracts. Non-limiting examples of natural extracts include glycoprotein extracts from species such as Trametes versicolor, Lion's Mane, Maitake, Milk Thistle, Artichoke, Turmeric, Dandelion, Rumex japonicus, Beetroot, and Ginger; terpenoid extracts containing pentacyclic triterpenes such as betulin, pentacyclic triterpene metabolites such as betulinic acid, transpyroin, losenolactone, sesquiterpenes, and erinasine; flavonoid extracts containing flavones, flavonols, flavanones, flavanols, bioflavonoids, or isoflavonoids; polysaccharide extracts containing PSP, PSK, CVG, HPB-3, H6PC20; or polycyclic aromatic molecules such as hericerine and hericenone.

[0219] Parts kit Another object of the present invention is to combine the first component comprising the nicotinamide mononucleotide derivative of the present invention described herein with other active ingredients, such as natural extracts; anti-cancer agents; antidepressants; antiretroviral agents; beta-blockers; antidiabetic agents; diuretics; antihypertensive agents; antiarrhythmic agents; CNS stimulants; antimalarial agents; immunosuppressants; antifungal agents; cytokines; interferons; anabolic steroids; adrenergic stimulants; neuromodulators; COX inhibitors; angiotensin-converting enzyme inhibitors; angiotensin receptor blockers; lanolazine; metformin; and electrocorticoid receptors. The kit comprises a second component containing an active ingredient selected from body antagonists; hydroxymethylglutaryl coenzyme A reductase inhibitors; antioxidants such as quercetin's self-nanoemulsifying formulations; Q10 coenzyme; vitamin E; L-carnitine; steroids; cyclosporine; mycophenolate mofetil; anti-TNF drugs such as influximab or etanercept; anti-IL1 such as Sraninka; anti-PGF such as Gleevec; anti-CD20 such as rituximab; maltol; PTEN modifiers; nobiletin; pyrroloquinoline quinone; and urolithin.

[0220] In one embodiment, the component kit of the present invention comprises a first component comprising compound 001 or a pharmaceutically acceptable salt or solvate thereof, and a second component comprising another active ingredient, such as the active ingredient described herein.

[0221] Treatment method The present invention also relates to the use of the nicotinamide mononucleotide derivatives or their pharmaceutical compositions herein in the treatment of anticancer drug-induced toxicity as described herein.

[0222] The present invention also relates to the use of the above-described nicotinamide mononucleotide derivatives in the manufacture of pharmaceuticals for the treatment of anticancer drug-induced toxicity described herein.

[0223] The present invention relates to a method for treating the above-described antineoplastic drug-induced toxicity in a subject requiring such treatment, comprising the step of administering a therapeutically effective amount of the above-described nicotinamide mononucleotide derivative or pharmaceutically active composition to the subject. [Brief explanation of the drawing]

[0224] [Figure 1] This histogram shows the survival rates of mice 5 days after DOX (20 mg / kg) or vehicle induction, with and without treatment. ##p<0.01: Comparison of vehicle-treated Dox mice and control mice by Fisher's test. £p<0.05, ££p<0.01: Comparison of vehicle-treated Dox mice and NMN analog-treated Dox mice by Fisher's test. [Figure 2A] This graph shows the change in body weight of mice treated with compounds 001, 010, and 011 (180 mg / kg) or a vehicle before (light gray symbols) and 5 days after (dark gray symbols) injection of physiological saline or DOX (20 mg / kg). £££p<0.001: Comparison of body weight before and 5 days after Dox injection by Bonferroni post-hoc test after two-way ANOVA. [Figure 2B]The following is a histogram showing the weight (BW) increase calculated as follows: BW on euthanasia date minus pre-injection BW for mice treated with Dox (20 mg / kg) and uninjected, and treated with compounds 001, 010 and 011 (180 mg / kg) or vehicle. ***p<0.001: Comparison of vehicle-treated Dox mice and control mice by Mann-Whitney test. $$p<0.01, $$$p<0.001: Comparison of vehicle-treated Dox mice and NMN analog-treated Dox mice by post-hoc Dunnett test after one-way ANOVA. [Figure 3] Histograms showing left ventricular (LV) end-diastolic volume (Figure 3A), end-systolic volume (Figure 3B), and ejection fraction (Figure 3C) 5 days after injection of physiological saline or DOX (20 mg / kg). **p<0.01, ***p<0.001: Comparison of vehicle-treated Dox mice and control mice by Mann-Whitney test. $p<0.05, $$$p<0.001: Comparison of vehicle-treated Dox mice and NMN analog-treated Dox mice by post-hoc Dunn test after Kruskal-Wallis test. [Figure 4] Histograms showing end-diastolic and end-systolic LV diameters (Figures 4A and 4B, respectively), internal diameter reduction rate (Figure 4C), and heart rate (Figure 4D) 5 days after injection of physiological saline or DOX (20 mg / kg). **p<0.01, ***p<0.001: Comparison of vehicle-treated Dox mice with control mice by t-test or Mann-Whitney test. $$$p<0.001: Comparison of vehicle-treated Dox mice with NMN analog (180 mg / kg) Dox mice by post-hoc Dunnett test or Kruskal-Wallis test after one-way ANOVA. [Figure 5] These histograms show the systolic and diastolic anterior wall thickness (Figures 5A and 5B, respectively) and systolic and diastolic posterior wall thickness (Figures 5C and 5D, respectively) 5 days after injection of physiological saline or DOX (20 mg / kg). *p<0.05, **p<0.01: Comparison of vehicle-treated Dox mice and control mice by Mann-Whitney test. [Figure 6]This is a histogram showing cardiac weight (Figure 6A) and cardiac weight normalized to tibia length (Figure 6B) 5 days after injection of physiological saline or DOX (20 mg / kg). ***p<0.001: Comparison of vehicle-treated Dox mice and control mice by t-test. [Figure 7] These are histograms showing LDH concentration (U / L, Figure 7A) and LDH (magnification change, Figure 7B) in mouse plasma 5 days after injection of physiological saline or DOX (20 mg / kg). **p<0.01: Comparison of vehicle-treated Dox mice and control mice by Mann-Whitney test; p<0.05: Comparison of vehicle-treated Dox mice and NMN analog (180 mg / kg)-treated Dox mice by Kruskal-Wallis test. [Examples]

[0225] The present invention is further illustrated by the following embodiments.

[0226] Example 1: Synthesis of the compound of the present invention Materials and methods All materials were obtained from the supplier and used without further purification. Thin-layer chromatography was performed using Merk silica gel 60F254 TLC plastic sheets (layer thickness 0.2 mm). Column chromatography purification was performed using silica gel 60 (70-230 mesh, ASTM, Merk). Melting points were determined using a digital melting point spectrometer (Electrothermal IA 8103) and left uncorrected, or determined using a Kofler bench-type WME (Wagner & Munz). IR, 1 H, 19 F and 13 ¹³C NMR spectra were used to confirm the structure of all compounds. IR spectra were recorded using a Perkin Elmer Spectrum 100 FT-IR spectrometer, and NMR spectra were recorded using Bruker AC 300, Advance DRX 400, and Advance DRX 500 spectrometers with CDCl3, CD3CN, D2O, or DMSO-d6 as solvents. 1 Regarding H spectra,13 Regarding the C spectrum, at 75 or 100 MHz, and 19 The F spectrum was recorded at 282 or 377 MHz. The chemical shift (δ) was indirectly obtained from (i) 1 Regarding H, CHCl3 (δ 7.27) and (ii) 13 Regarding C, the signal of CDCl3 (δ77.2), and directly (iii) 19 F is expressed as parts per million relative to the signal of CFCl3 (internal standard) (δ0). Chemical shifts are given in ppm, and peak multiplicity is denoted as follows: s = single line, br d = broad single line, d = double line, dd = double line of double lines, t = triple line, q = quadruple line, quint = quintue line, m = multiple lines). High-resolution mass spectrometry (HRMS) was obtained from the "Service sentral d'analyse de Solaize" (Centre national de la recherche scientifique) and recorded using a Waters spectrometer with electrospray TOF ionization (ESI-TOF).

[0227] General experimental procedure Step 1: Synthesis of the compound of formula (Ali) Dissolve 1.0 equivalent of the compound of formula (Di) in dichloromethane. Add 1.5 equivalents of nicotinamide (Ei) and 1.55 equivalents of TMSOTf (Ei) at room temperature. Heat the reaction mixture under reflux and stir until the reaction is complete. Cool the mixture to room temperature and filter it. Concentrate the filtrate to dryness to give the tetraacetate (Ali).

[0228] Step 2: Synthesis of Compound 005 Dissolve tetraacetate (Ali) in methanol and cool to -10°C. Add 4.6 M ammonia in methanol (3.0 equivalents) at -10°C and stir the mixture at this temperature until the reaction is complete. Add Dowex HCR(H+) resin until the pH reaches 6-7. Heat the reaction mixture to 0°C and filter. Wash the resin with a mixture of methanol and acetonitrile. Concentrate the filtrate to dryness. Dissolve the residue in acetonitrile and concentrate to dryness. Dissolve the residue in acetonitrile to give a solution of compound 005.

[0229] Step 3: Synthesis of the compound of formula (Bi) Dilute the solution of crude compound 005 in acetonitrile with trimethyl phosphate (10.0 equivalents). Distill the acetonitrile under vacuum and cool the mixture to -10°C. Add phosphorus oxychloride (4.0 equivalents) at 10°C and stir the mixture at 10°C until the reaction is complete.

[0230] Steps 4 and 5: Synthesis of compounds 001 and 009 The mixture obtained in step 3 is hydrolyzed by adding methyl tert-butyl ether after adding a 50 / 50 mixture of acetonitrile and water. The mixture is filtered, and the solid is dissolved in water. The aqueous solution is neutralized by adding sodium bicarbonate and extracted with dichloromethane. The aqueous phase is concentrated to dryness to give a crude mixture of compound 001 and compound 009.

[0231] Compounds 001 and 009 are separated by purification using a Dowex 50wx8 filter with water elution. The fraction containing compound 001 is concentrated and further purified by silica gel chromatography. The fraction containing compound 009 is concentrated to dryness. The residue is purified by silica gel column chromatography (isopropanol / water gradient). The pure fractions are combined and concentrated. The residue is freeze-dried to produce compound 009 as a beige solid.

[0232] Characterization of compound 009: 31P RMN: δ (ppm, refer to 0 ppm in 85% H3PO4:D2O) = -11.72; 1 H RMN: δ (ppm, refer to TMS: 0ppm in D2O) = 4.20 (ddd, J H-H =11.9,3.5,2.4Hz,2H),4,35(ddd,J H-H =11.9,3.9,2.2Hz,2H),4.43(dd,JH-H=5,0,2.6Hz,2H),4.53(t,JH-H=5.0Hz,2H),4.59(m,2H) ,6.16(d,JH-H=5.4Hz,2H),8.26(dd,JH-H=8.1,6.3Hz,2H),8.93(d,JH-H=8.1Hz,2H),9.25(d,J H-H =6.2Hz, 2H), 9.41(s, 2H); 13 C RMN:δ (ppm, refer to TMS: 0ppm in D2O)=64.84(CH2),70.73(CH),77.52(CH),87.11(CH),99.88(CH),128.65(CH),133.89( Cq), 139.84(CH), 142.54(CH), 146.04(CH), 165.64(Cq); MS(ES+): m / z=122.8[Mニコチンアミド+H]+, 650.8(M+H)+.

[0233] Synthesis of compound 010 Add phosphorus oxychloride (3.0 equivalents) to trimethyl phosphate (20.0 equivalents) at -5°C. Gradually add β-NR chloride (β-NMN chloride) (1.0 equivalent) at -5°C and stir the reaction mixture overnight at -5°C. Add morpholine (3.0 equivalents) dropwise at -10 / 0°C and stir the mixture for 2-3 hours. Subsequently, add α-NMN (compound 002) (1.0 equivalent) dropwise at -5°C and stir the reaction mixture overnight at -5°C. Hydrolysis is carried out by dropwise addition of water (5 volumes) at -10 / 0°C and stir the mixture at 10-15°C until completely homogenized. Then, extract the reaction mixture with dichloromethane (6 × 10 volumes) and neutralize the aqueous phase by elution through formate form Purolite A600E resin (theoretical amount to neutralize HCl generated from POCl3). Subsequently, the eluent is vacuum concentrated at 45 / 50°C to obtain a crude product containing αβ-diNMN (compound 010). 100~200 mesh H + Some impurities can be removed by elution with water through the Dowex 50wx8 resin. The fraction containing compound 010 is collected and concentrated under vacuum at 45-50°C. The crude product is then purified by preparative chromatography using a Luna Polar RP 10μm stationary phase, eluting with a 10mM NaH2PO4 aqueous solution. The pure fraction is collected and H + Form of Purolite C100EH resin (Na + to H + It dissolves in water by the amount required to completely replace it, and then Purolite A600E resin (H2PO4) in acetic acid form. - Elute the compound (in the amount necessary to completely replace it with acetate) with the eluent. The eluent is concentrated under vacuum, and the residue is freeze-dried to produce compound 010 as a white solid.

[0234] 31 P RMN:δ(ppm, reference 0 ppm in 85% H3PO4:D2O) = -11.87, -11.69, -11.46, -11.29; 1H RMN:δ(ppm, reference TMS: 0ppm in D2O)=4.10(ddd,J=11.1,6.1,3.1Hz,1H),4.15-4.25(m,2H),4.36(ddd,J=12.2,4.4,2.4Hz,1H),4.40(dd ,J=4.9,2.4Hz,1H),4.44(dd,J=5.0,2.7Hz,1H),4.53(t,J=5.0Hz,1H),4.5(m,1H),4.85(m,1H),4.92(t,J=5.3Hz ,1H),6.15(d,J=5.5Hz,1H),6.51(d,J=5.7Hz,1H),8.14(dd,J=8.0,6.3Hz,1H),8.26(dd,J=8.1,6.3Hz,1H),8.8 8(d,J=8.1Hz,1H),8.92(d,J=8.1Hz,1H),9.02(d,J=6.3Hz,1H),9.24(s,1H),9.26(d,J=6.4Hz,1H),9.40(s,1H); 13 C RMN:δ(ppm, reference TMS: 0 ppm in D2O)=64.83,64.87(CH2),65.30,65.35(CH2),70.65(CH),70.74(CH),71.92(CH),77.51(CH),87.03,87.10(CH),87.19,87.26(CH),96.57(CH),99.83(CH),126.89(CH), 128.54(CH), 132.44(Cq), 133.81(Cq), 139.85(CH), 140.92(CH), 142.50(CH), 143.49(CH), 145.06(CH), 145.97(CH), 165.64(Cq), 165.88(Cq); MS(ES+): m / z = 122.8[M nicotinamide + H]+, 650.9[M + H]+.

[0235] Synthesis of the compound of formula 011 Add phosphorus oxychloride (3.0 equivalents) to trimethyl phosphate (20.0 equivalents) at -5°C. Gradually add α-NR chloride (1.0 equivalent) at -5°C and stir the reaction mixture overnight at -5°C. Add morpholine (3.0 equivalents) dropwise at -10 / 0°C and stir the mixture for 2-3 hours. Then add α-NMN (compound 002) (1.0 equivalent) dropwise at -5°C and stir the reaction mixture overnight at -5°C. Hydrolysis is carried out by dropwise addition of water (5 volumes) at -10 / 0°C and stir the mixture at 10-15°C until completely homogenized. Subsequently, extract the reaction mixture with dichloromethane (6 × 10 volumes) and neutralize the aqueous phase by elution through Purolite A600E resin in formate form (theoretical amount to neutralize HCl generated from POCl3). Subsequently, the eluent is vacuum concentrated at 45 / 50°C to obtain a crude product containing αα-diNMN (compound 011). 100~200 mesh H + Some impurities can be removed by elution with water through the Dowex 50wx8 resin. The fraction containing compound 011 is collected and concentrated under vacuum at 45-50°C. The crude product is then purified by preparative chromatography using a Luna Polar RP 10μm stationary phase, eluting with a 10mM NaH2PO4 aqueous solution. The pure fraction is collected and H + Form of Purolite C100EH resin (Na + to H + It dissolves in water by the amount required to completely replace it, and then Purolite A600E resin (H2PO4) in acetic acid form. - Elute the compound (in an amount necessary to completely replace it with acetate). The eluent is concentrated under vacuum, and the residue is freeze-dried to produce compound 011 as a white solid.

[0236] 31 P RMN:δ(ppm, reference 0 ppm in 85% H3PO4:D2O) = -11.40; 1H RMN: δ(ppm, reference TMS: 0ppm in D2O)=4.14(ddd,J=11.4,3.4,2.8Hz,2H),4.23(ddd,J=11.6,3.3,2.8Hz,2H),4.44(dd,J=4.8,2.3Hz,2H),4.88( m,2H),4.96(t,J=5.3Hz,2H),6.54(d,J=5.7Hz,2H),8.15(dd,J=8.1,6.2Hz,2H),8.89(d,J=8.1Hz,2H),9.05(d,J=6.3Hz,2H),9.26(s,2H); 13 C RMN:δ(ppm, reference TMS:0ppm in D2O)=65.37(CH2),70.70(CH),71.95(CH),87.30(CH),96.62(CH),126.91(CH),132.45(Cq),140.94(CH),143.52(CH),145.07(CH),165.90(Cq);MS(ES+):m / z=122.7(M nicotinamide + H)+,650.8(M + H)+.

[0237] Example 2: Evaluation of the compound of the present invention in a model of doxorubicin-induced cardiotoxicity The objective of this study was to evaluate the effect of 180 mg / kg of intravenous administration of compounds 001, 010, and 011 on the progression of doxorubicin-induced cardiotoxicity.

[0238] I. Materials and Methods material Animals: 76 male mice, 8 weeks old upon arrival, were obtained from Janvier Labs at Le Genest St Isle, 53941 St Berthevin, France. Each animal was identified using an electronic chip. Each cage was numbered. Based on the animal number / cage and the number of cages, the animals were assigned unique numbers including the group name and mouse number. Matching cards used to identify the cages housing the experimental animals contained the following information: name of the experiment, number of the experiment, and cage number.

[0239] Compounds: Compounds 001, 010, and 011 were prepared or purchased according to Example 1 and stored at +4°C until use. The vehicle was a physiological buffer.

[0240] method 1. Preparation of the formulation Compounds 001, 010, and 011 (180 mg / kg) were dissolved in a vehicle (the solution was used at room temperature for up to 1 day). A fresh sample for each dose was prepared daily, except for the weekend (the solution was prepared on Saturday and used on Saturday and Sunday).

[0241] 2. Doxorubicin-induced cardiotoxicity Cardiotoxicity was induced by a single intraperitoneal injection of 20 mg / kg of doxorubicin (DOX). Doxorubicin was prepared at 2 mg / mL, and the administered volume was 10 mL / kg.

[0242] The mortality rate was tracked throughout the entire duration of the experiment.

[0243] 3. Experimental group Group description: Group 1: Vehicle (ip) Group 2: Doxorubicin (20 mg / kg) Group 3: Doxorubicin (20 mg / kg) + Compound 001 180 mg / kg Group 4: Doxorubicin (20 mg / kg) + Compound 010 180 mg / kg Group 5: Doxorubicin (20 mg / kg) + Compound 011 180 mg / kg

[0244] Group allocation Each group contains 14 to 24 mice.

[0245] As per the regulations for non-clinical studies, the test and control animal groups were maintained under identical conditions. The intended test period was 11 days.

[0246] 4. Induction by doxorubicin DOX (20 mg / kg) was administered to mice via the intraperitoneal route during day D0.

[0247] 5. Treatment Treatment with compounds 001, 010, and 011 was initiated once daily from D5 to D0, starting 5 days before the DOX injection.

[0248] Mice were treated with compounds 001, 010, and 011 30 minutes before DOX injection.

[0249] Mice were treated with compounds 001, 010, and 011 once daily during the experimental period (D0-D5). They were euthanized 24 hours after the last injection.

[0250] 6. Body weight, survival rate, and clinical tests Weight was assessed at registration and on D5.

[0251] The survival rate was recorded daily until the end of the experiment (D5).

[0252] 7. Collection of blood and urine Postorbital blood samples were collected at registration and on days 1 and 5 after DOX induction to evaluate biomarkers (particularly LDH).

[0253] 8. Organ harvesting On day 5, the heart and tibia were harvested.

[0254] 9. Evaluation of cardiac function by electrocardiogram (ECG) Electrocardiograms (ECGs) were performed five days after doxorubicin injection in animals under anesthesia (isoflurane 1.5-2%) using a non-invasive two-dimensional ECG (VF16-5 probe, Siemens, Acuson NX3 Elite). After removing lumbar hair, numerous images of the heart were obtained in both parasternal longitudinal and uniaxial views.

[0255] The following cardiac functions were assessed during the ECG: - End-systolic and end-diastolic diameters of the left ventricle (LV); - LV end-systolic and end-diastolic volumes - Inner diameter reduction ratio; - Heart rate; and - Anterior and posterior wall thickness during diastole and systole.

[0256] II. Results and Discussion 1.Survival rate Figure 1 shows the survival rate 5 days after doxorubicin injection in mice induced by DOX (20 mg / kg) and mice that were not induced.

[0257] DOX mice were treated with compounds 001, 010, and 011 (180 mg / kg) or a vehicle.

[0258] As shown, nearly 50% of the doxorubicin-treated mice were killed before the end of the experimental protocol.

[0259] Treatment with compound 001 tended to improve survival rates (78% survival), but did not reach statistical significance, likely due to a crossover of survival curves. However, treatment with compound 010 or 011 significantly improved survival rates (98% and 100% survival, respectively) compared to the untreated group (50% survival).

[0260] 2. Weight Figure 2A shows the changes in body weight of mice treated with compounds 001, 010, and 011 (180 mg / kg) or a vehicle before (light gray symbols) and 5 days after (dark gray symbols) injection of physiological saline or DOX (20 mg / kg).

[0261] Figure 2B shows the weight (BW) increase calculated as follows: weight on the day of euthanasia - weight before injection.

[0262] Surviving vehicle-treated mice showed signs of major morbidity associated with severe weight loss (-4.2 ± 0.5 g). Weight loss observed after doxorubicin administration was significantly reduced by compounds 001, 010, and 011 (p<0.01, p<0.001, and p<0.001, respectively).

[0263] 3. Cardiac function 3.1. Left ventricular diastolic / end-systolic volume and ejection fraction Figure 3 shows the left ventricular (LV) end-diastolic volume (Figure 3A), end-systolic volume (Figure 3B), and ejection fraction (Figure 3C) 5 days after injection of physiological saline or DOX (20 mg / kg) with and without treatment with compounds 001, 010, and 011.

[0264] As shown in Figure 3, doxorubicin induced a significant increase in LV (left ventricular) end-systolic volume compared to the control group (Figure 3B), but there was no significant difference in end-diastolic volume (Figure 3A), and it resulted in a large decrease in ejection fraction (comparison between doxorubicin vehicle group 38.9±1.3% and control mice 64.8±0.6%) (Figure 3C).

[0265] Compared to DOX-induced animals administered with the vehicle, compounds 001, 010, and 011 reduced the end-systolic volume (LV) compared to the doxorubicin vehicle group (Figure 3B), with compound 010 showing a statistically significant difference (p<0.05).

[0266] Ejection rates were significantly improved after treatment with compounds 001, 010, and 011 compared to untreated DOX animals (56.9±0.6% (p<0.05) in doxorubicin mice treated with NMN, 58.2±0.5% (p<0.001) in doxorubicin mice treated with compound 011, and 60.0±0.6% (p<0.001) in doxorubicin mice treated with compound 010) (Figure 3C).

[0267] 3.2. Left ventricular end-systolic / diastolic diameter, internal diameter shortening percentage, and heart rate Figure 4 shows the end-diastolic and end-systolic diameters of the pulmonary vein (LV) (Figures 4A and 4B, respectively), the percentage reduction in internal diameter (Figure 4C), and the heart rate (Figure 4D) 5 days after injection of physiological saline or DOX (20 mg / kg).

[0268] As shown in Figure 4, in doxorubicin-treated mice, the LV inner diameter significantly increased during systole (Figure 4B), showed no significant difference during diastole (Figure 4A), and resulted in a decrease in the inner diameter shortening rate (33.5±0.4% compared to 43.2±0.5% in the control group) (Figure 4C). Treatment with compounds 001, 010, and 011 significantly improved the inner diameter shortening rate to approximately 38% (p<0.001 across all three groups).

[0269] Furthermore, doxorubicin significantly reduced heart rate compared to control mice (compared to 365.1±23.9 bpm and 525.6±19.8 bpm, respectively). Treatment with compounds 001, 010, and 011 resulted in an increase in heart rate, with compound 010 significantly improving this parameter (470.1±18.8 bpm (p<0.001)).

[0270] 3.3. Left ventricular anterior and posterior wall thickness during systole and diastole Figure 5 shows the systolic and diastolic anterior wall thickness (Figures 5A and 5B, respectively) and the systolic and diastolic posterior wall thickness (Figures 5C and 5D, respectively) 5 days after injection of physiological saline or DOX (20 mg / kg).

[0271] Doxorubicin significantly reduced anterior and posterior wall thickness during systole, but not during diastole, and both treatments had a significant effect.

[0272] Treatment of DOX mice with compounds 001, 010, and 011 (180 mg / kg) resulted in a non-significant increase in anterior and posterior systolic wall thickness.

[0273] 4. Heart weight Figure 6 shows cardiac weight (Figure 6A) and cardiac weight normalized to tibia length (Figure 6B) 5 days after injection of physiological saline or DOX (20 mg / kg).

[0274] Dox mice were treated with compounds 001, 010, and 011 (180 mg / kg) or a vehicle.

[0275] As shown in Figures 6A and 6B, doxorubicin significantly reduced heart weight compared to control mice (compared to 102.3 ± 4.6 mg and 128.9 ± 3.3 mg, respectively). Treatment with compounds 010 and 011 tended to increase heart weight, but the increase was not statistically significant compared to DOX vehicle mice. Similar results were obtained when heart weight was normalized relative to tibial length.

[0276] 5. Evaluation of biomarkers Figure 7 shows the LDH concentration (U / L, Figure 7A) and LDH (magnification change, Figure 7B) in mouse plasma 5 days after injection of physiological saline or DOX (20 mg / kg).

[0277] Dox mice were treated with compounds 001, 010, and 011 (180 mg / kg) or a vehicle.

[0278] Plasma LDH (lactate dehydrogenase) was measured 5 days after doxorubicin injection. As shown in Figures 7A and 7B, doxorubicin induced cell damage, as indicated by a more than threefold increase in LDH release compared to the control group. Treatment with NMN reduced LDL release by more than 35%, but this was not statistically significant. However, treatment with both compounds 010 and 011 had a significant effect, including a 50–55% reduction in LDL levels (p<0.05).

[0279] III. Conclusion In summary, the results showed that doxorubicin induces cardiac injury in addition to dysfunctional impairment characterized by impaired myocardial contractility and cardiac filling. Doxorubicin also resulted in a high mortality rate and severe weight loss.

[0280] Treatment with compounds 001, 010, and 011 significantly improved survival rates and weight loss, and prevented a decline in cardiac function, as indicated by the effects of the treatment on ejection fraction, diameter shortening rate, and heart rate.

Claims

1. A pharmaceutical composition for use in the treatment of anticancer drug-induced cardiotoxicity, comprising a compound of formula (I). 【Chemistry 1】 or a pharmaceutically acceptable salt or solvate thereof (In the formula, X is O; R １ H is; R ２ , R ３ , R ４ and R ５ These are independently selected from H and hydroxyl; R ６ H is; R ７ is POR ９ R １０ and 【Chemistry 2】 Selected from; here, R ９ and R １０ These are independently selected from OH and OR11; here - R １１ is, (C １ ~C １０ ) alkyl, (C ３ ~C １０ ) Cycloalkyl, (C ５ ~C １２ ) Aryl, (C １ ~C １０ ) Alkyl-(C ５ ~C １２ ) Aryl, substitution (C ５ ~C １２ ) Aryl, (C １ ~C １０ ) Heteroalkyl, (C １ ~C １０ ) Haloalkyl, -(CH ２ ) ｍ C(O)(C １ ~C １５ ) alkyl, -(CH ２ ) ｍ OC(O)(C １ ~C １５ ) alkyl, -(CH ２ ) ｍ OC(O)O(C １ ~C １５ ) alkyl, -(CH ２ ) ｍ SC(O)(C １ ~C １５ ) alkyl, -(CH ２ ) ｍ C(O)O(C １ ~C １５ ) alkyl, -(CH ２ ) ｍ C(O)O(C １ ~C １５ ) Alkyl-(C ５ ~C １２ )aryl (where m is an integer selected from 1 to 8) and -P(O)(OH)OP(O)(OH) ２ , as well as selected from internal or external counterions; X' is O; R １’ H is; R ２’ , R ３’ , R ４’ and R ５’ These are independently selected from H and hydroxyl; R ６’ H is; R ８’ NH 2 is; Y' is selected from CH and CH2; n is 2; 【Transformation 3】 represents a junction; 【Chemistry 4】 Y' represents a single or double bond; 【Transformation 5】 R １’ Depending on its position, it represents either an alpha or beta anomer; R ８ NH 2 is; Y is selected from CH and CH2; 【Transformation 6】 Y represents a single or double bond; 【Transformation 7】 R １ (Depending on the position, it represents either an alpha or beta anomer.) A pharmaceutical composition containing the above.

2. R ３ and R ４ A pharmaceutical composition for use according to claim 1, wherein the two are identical and represent hydrogen.

3. R ２ and R ５ A pharmaceutical composition for use according to claim 1 or 2, wherein the OH group is identical to the OH group.

4. The compound is Table 1 A pharmaceutical composition for use according to any one of claims 1 to 3, further selected from pharmaceutically acceptable salts and solvates thereof.

5. A pharmaceutical composition for use according to any one of claims 1 to 4, wherein the cardiotoxicity is induced by an anti-cancer agent selected from anthracyclines, alkylating agents, taxanes, antimetabolites, bioresponse modifiers, histone deacetylase inhibitors, hormones, vinca alkaloids, topoisomerase inhibitors, monoclonal antibodies, tyrosine kinase inhibitors, and mixtures thereof.

6. A pharmaceutical composition for use according to any one of claims 1 to 5, wherein the cardiotoxicity is induced by an anthracycline selected from doxorubicin, daunorubicin, epirubicin, idarubicin, bleomycin, mitomycin, mitoxantrone, plicamycin, and barurubicin.

7. The pharmaceutical composition for use according to any one of claims 1 to 6, wherein the cardiotoxicity is induced by doxorubicin.

8. A pharmaceutical composition for use according to any one of claims 1 to 7, wherein the cardiotoxicity is selected from heart failure, left ventricular failure, myocardial ischemia, myocardial infarction, QT prolongation, torsades de pointe, arrhythmia, pericarditis, myocarditis, bradycardia, hypertension, and thromboembolism.

9. Natural extracts; antineoplastic agents; antidepressants; antiretroviral agents; beta-blockers; antidiabetic agents; diuretics; antihypertensive agents; antiarrhythmic agents; CNS stimulants; antimalarial agents; immunosuppressants; antifungal agents; cytokines; interferons; anabolic steroids; adrenergic stimulants; neuromodulators; COX inhibitors; angiotensin-converting enzyme inhibitors; angiotensin receptor blockers; lanolazine; metformin; electrolyte corticosteroid receptor antagonists; hydroxymethylglutaryl coenzyme A reductase inhibitors; Kel A pharmaceutical composition for use according to any one of claims 1 to 8, further comprising at least one active ingredient selected from: antioxidants such as cetine self-nanoemulsifying formulations; Q10 coenzyme; vitamin E; L-carnitine; steroids; cyclosporine; mycophenolate mofetil; anti-TNF drugs such as influximab or etanercept; anti-IL1 such as Sraninka; anti-PGF such as Gleevec; anti-CD20 such as rituximab; maltol; PTEN modifiers; nobiletin; pyrroloquinoline quinone; and urolithin.

Images